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Other authors in this book have provided an excellent review of the potential environ-
mental, health, and safety (EHS) concerns accompanying the manufacturing and/or use 
of select nanoscale materials which may occur under certain conditions. These potential 
concerns include exposure through dermal penetration and/or inhalation, possible trans-
location through the bloodstream, accumulation in various organs, and theoretical pen-
etration through cell membranes and the blood–brain barrier (Oberdörster et al., 2005; 
Gwinn and Vallyathan, 2006; Maynard et al., 2011; Foss Hansen et al., 2013). There is 
also concern that engineered nanoscale materials may adversely affect the environment 
in the event of unintended releases. Simply put, there is a worry that because engineered 
nanoscale materials are so small and often have unique properties, they may be able to 
iniltrate the human body and the environment in ways which larger particles cannot, 
and once there, may cause unique adverse EHS consequences (Maysinger et al., 2006).
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1  Liebeck V. McDonald’s Restaurants, P.T.S., Inc., No. D-202 VS-93-02419, 1995 WL 36039 (N.M. 
Dist. Ct. 1994), but see, McMahon v. Bunn-O-Matic Corp., et al., 150 F.3d 651 (7th Cir. 1997).
While the science is currently inconclusive, some initial studies support theoreti-
cal cause for concern (Maynard et al., 2006). In this modern legal age of successful 
tort lawsuits over spilled hot coffee,1 these potential EHS concerns produce liability 
and regulatory anxiety for businesses venturing into the ield of nanotechnology, as 
well as their investors, insurers, and customers. While many of these concerns are 
not unique to nanotechnology, it is rare that so many novel legal issues are arrayed 
all at once. Legal issues intersecting with nanotechnology research, development, 
and commercialization include intellectual property (IP), workplace and occupa-
tional liability, commercial/contractual liability, environmental regulation, food and 
drug regulation, consumer product safety, tort and product liability, and end-of-life 
disposal issues. It can be a daunting legal web to untangle unless analyzed piece by 
piece, one step at a time.
At the same time, nanotechnology businesses must take a holistic view of the 
interrelated legal issues they may confront over their lives. A single legal issue can-
not be viewed in isolation, as it often implicates additional areas of commerce which 
can impact predictable outcomes. Depending upon where they it into the life cycle 
of a nano-enabled product, businesses will experience varying types and amounts of 
potential legal exposure which must be managed proactively. The alternative is to cross 
one’s ingers and hope for the best or attempt to solve legal problems after the fact 
which is often time consuming, nerve racking, and expensive. Moreover, in Europe 
there is a well-documented example of how regulatory uncertainty coupled with public 
anxiety, may nearly kill off an industry, seriously hindering it to reach its full potential. 
That of course is the example of the European regulatory framework for genetically 
modiied organisms (GMOs).
12.1 Nano-product legal life cycle
For conceptual purposes, the legal life cycle of a nanotechnology product has ive 
distinct stages:
1. Supply
2. Manufacturing
3. Intermediate use
4. Consumer
5. End-of-life disposal.
A business involved in making, selling, or distributing a product incorporat-
ing engineered nanoscale materials may be involved in any, several, or all of these 
ive stages. While each stage may have multiple subparts in any given scenario, the 
ive basic stages provide a useful backdrop for discussion. Once the ive stages 
are explained, a basic legal framework can be superimposed which provides any 
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nanotechnology-based business with a basic guide on how to spot and manage poten-
tial legal and regulatory needs. Of course, these ive stages are only a starting point. 
Real life businesses involved in nanotechnology will undoubtedly face more compli-
cated life cycles which relect their individual facts and circumstances. This framework 
is lexible enough, however, to be modiied to embrace such changes (Figure 12.1).
12.1.1 Supply stage
The irst stage in the conceptual nanotechnology product legal life cycle is the “sup-
ply stage.” A supplier is a company that does not make a inal nanotechnology-based 
product (nano-product), but rather creates a precursor which it then sells to others. A 
supplier can make any number of precursors and sell them to a variety of other suppli-
ers and/or manufacturers. Take, for example, a carbon nanotube manufacturer which 
makes single-walled carbon nanotubes (SWCNTs) and then sells them as raw material 
to third parties who in turn use them to make new, innovative products. The SWCNTs 
may be made to a particular customer’s speciications or they may be generic in the 
sense that the supplier makes only one type and purchasers are free to buy them or not. 
For our purposes, if all a company does is make and sell SWCNTs to other companies, 
it is considered a supplier. Suppliers may also develop and commercialize traditional 
chemical substances as well as equipment and IP used by nano-manufacturers in their 
own internal processes. Additionally, there may be several hierarchies of suppliers, 
each supplying the next with a subcomponent or submaterial necessary to advance the 
whole through completion. On the other hand, suppliers may not always form a direct 
chain, with several suppliers acting in parallel to supply a single, master supplier or 
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FIGURE 12.1
Nanotechnology product legal life cycle.
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manufacturer with precursor materials. In such instances, the analogy is a wheel, with 
the main supplier or manufacturer representing the hub and the unrelated suppliers rep-
resenting spokes. Finally, when a material leaves a supplier’s hands it is considered to 
be that company’s “product” for legal purposes.
12.1.2 Manufacturing stage
The second stage in the nanotechnology product legal life cycle—manufacturing—most 
often comes to mind when someone explains that their company is making a new nano-
technology product—some type of end product that can be held and/or seen. A com-
pany may make and supply its own raw nanomaterial—in our example SWCNTs—but 
what makes it a manufacturer for the purposes of our legal framework is that the com-
pany actually creates a inished product using the material. For example, a sporting 
goods’ manufacturer may purchase SWCNTs or other precursor chemical substances 
from a supplier and then mix them in a resin in its own manufacturing facility which 
is then pressed and heated to form an extremely light and strong piece of sports equip-
ment. This, of course, is an over simpliication of the process. For conceptual purposes, 
picture a loading dock at the back of a manufacturing facility. An inspector opening one 
of the boxes being shipped out will ind an actual product that typical consumers will 
recognize; the sports equipment in our example. Again, when the item leaves a manu-
facturer’s hands it is considered to be that company’s “product” for legal purposes. As 
noted above, the “supply” and “manufacturing” stages may overlap and may be hard 
to distinguish from each other at times. The main distinction for purposes of our frame-
work is the degree of inish exhibited by the product.
12.1.3 Intermediate use stage
The third stage in the nanotechnology product legal life cycle—intermediate use—
occurs when a business takes a completed product of another company and then incor-
porates it into its own product. An example is an automobile company that purchases 
fully made car batteries which use carbon nanotubes as energy storage media and then 
incorporates these batteries into its new electric hybrid vehicles. The ultimate product 
sold to the consumer—the car, incorporates the completed intermediate product—the 
battery, creating a linking distribution chain before ultimate purchase and use by a con-
sumer. In modern commerce, it is not unusual for a product to pass through several 
intermediate use stages before it is ultimately sold to the consuming public. Beyond 
merely incorporating other companies’ products into their own, an intermediate user 
may also be a distributor—a company that purchases a inished product from another 
company and then sells it to customers or relabels and sells it as its own.
12.1.4 Consumer stage
The fourth stage in our nanotechnology legal product life cycle is the “consumer” stage. 
This stage is reached when an ultimate product is sold into the hands of “Joe and Jane 
Public” who then use the product for its intended (and sometime unintended) purpose.
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The Project on Emerging Nanotechnologies (Project on Emerging 
Nanotechnologies, 2008) at the Woodrow Wilson International Center for Scholars 
publishes a useful online inventory of existing consumer products claiming to con-
tain engineered nanoscale materials. Although the inventory has American origins, 
its use is global. As of December 2012, there were 1317 consumer products on the 
inventory—ranging from appliances, automotive applications, electronics and com-
puters, food and beverage containers, dietary supplements, health and itness items, 
cosmetics, personal care products, and home and garden products, produced by 587 
companies, located in 30 countries. While not claiming to be comprehensive, the 
inventory is arguably the best available. Users of the inventory, however, should 
realize that the label “nano” is sometimes used as a marketing tool, and any given 
product on the inventory may not truly be considered a nanotechnology product. 
Additionally, many products on the inventory may have never been actually sold or 
marketed in the real world. So, use the inventory, but take it with a grain of salt.
For speciic information on nanomaterial-containing products marketed in the 
European Union (EU), recourse may be to the ANEC/BEUC 2010 inventory, created 
by two leading European consumers’ organizations. The inventory currently contains 
475 products, covering a wide range of industries. In addition, calls have been made 
to the European Commission, for it to consider the introduction of an inventory or 
database containing information on the different types and uses of nanomaterials on 
the EU market.2 In response to such calls, the European Commission (i) commis-
sioned a study (2010) on the development of an inventory for consumer products 
containing nanomaterials,3 which developed a model to record nanomaterial-related 
information in a structured manner, devised a methodology to identify nanomaterial-
containing products on the market and created a sample database populated with 
approximately 200 such products and (ii) announced a plan (European Commission, 
2012a) to host an inventory in the form of a web platform on nanomaterial types and 
uses, including safety aspects, which would enable users to retrieve data on nanoma-
terials and link it to the main information sources and databases.4 Finally, it should 
be noted that a number of EU Member States such as Belgium, Denmark, Germany, 
and Italy are, reportedly, considering the introduction of national product registries 
for nanomaterials, while France has been the irst one to actually enforce a national 
mandatory reporting scheme for nanomaterials as of January 1, 2013.5 As a result, 
it is expected that in the years to come increasingly comprehensive inventories of 
2  See, e.g., the European Parliament (2009), and the conclusions reached by the Council of the EU (2010).
3  Available at: http://ec.europa.eu/environment/chemicals/nanotech/index.htm.
4  Communication from the Commission to the European Parliament, the Council and the European 
Economic and Social Committee, Second Regulatory Review on Nanomaterials, COM(2012) 572 
inal, 3.10.2012.
5  Décret no 2012-232 du 17 février 2012 relatif à la déclaration annuelle des substances à l’état 
nanoparticulaire pris en application de l’article L. 523-4 du code de l’environnement, JORF 43, 
19.02.2012, page 2863; and Arrêté du 6 août 2012 relatif au contenu et aux conditions de présenta-
tion de la déclaration annuelle des substances à l’état nanoparticulaire, pris en application des articles 
R. 523-12 et R. 523-13 du code de l’environnement, JORF 185, 10.08.2012, p. 13166.
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nanomaterial-containing consumer products that are marketed in the EU will become 
available.
12.1.5 Disposal stage
The ifth and last stage of the conceptual nanotechnology legal product life cycle is the 
“disposal” stage. “Joe and Jane Public” are done using the product after its intended 
useful life and then get rid of it—usually by throwing it in the trash where it ultimately 
ends up in a landill or less often in an unregulated dump. For our purposes, this stage 
also includes more than just traditional disposal. For example, a shampoo containing a 
nanoscale material is considered “disposed of” in our scheme when it is washed down 
the bathtub drain after cleaning the user’s hair. Thus, it is not “thrown away” in a tradi-
tional sense, but it nonetheless enters the disposal chain for framework purposes. The 
supply, manufacturing, and intermediate use stages also present disposal issues for by-
products of the manufacturing process and for unused materials. These present disposal 
scenarios are typically covered by federal, state, and local environmental regulations.
While this ive-stage nanotechnology legal product life cycle is very basic and 
must be modiied in any real life scenario, it provides a useful construct for discuss-
ing potential legal and liability issues facing businesses involved in nanotechnology.
12.2 Legal issues
Superimposed on our ive-stage nanotechnology legal product life cycle are ive 
categories of primary legal issues:
1. Intellectual property
2. Workplace and occupational liability
3. Commercial and contractual liability
4. Government regulation
5. Product and tort liability.
As we work our way through these legal issues as they speciically pertain to 
engineered nanoscale materials, the overarching “take away point” for nanotechnol-
ogy companies is that they should have a full understanding of the potential legal 
issues relevant to each stage of the product life cycle. Any pertinent information 
regarding potential EHS risks should be accompanied by full and complete written 
disclosures which should be adequately documented. Additionally, retaining coun-
sel fully versed in nanotechnology will reduce risk of unforeseen legal problems 
with IP, commercial relationships, and contracts.
12.2.1 Intellectual property
IP legal issues confronting nanotechnology commercialization primarily accom-
pany the supply stage and/or design and engineering phases of the manufacturing 
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6  See also Bawa (2004), who has stated that, “[i]ntellectual property, a product or creation of the 
human mind, is an intangible asset representing humankind’s only truly inexhaustible resource.”
7  US Const. art. I, § 8, cl. 8, available at http://www.law.cornell.edu/constitution/constitution. 
articlei.html; see also Graham v. John Deere Co. of Kansas City, 383 US 1 (1996), available at http://
supreme.justia.com/us/383/1/case.html.
stage. It is in the early supply and manufacturing stages before the irst nano-prod-
uct is ever stamped, pressed, molded, or otherwise created that a business must take 
all steps necessary to protect the value of its invention. Without protection from 
potential misappropriation, there can be no successful commercialization of new 
ideas (Smith and Parr, 2005).6 For the purposes of our framework, IP includes pat-
ents, trademarks, and trade secrets (Figure 12.2).
12.2.1.1 Patents
Patents are granted by governments and are the legal right to exclude others from 
using an invention for a ixed period of time in exchange for publication of a com-
plete explanation of what the invention is, what it does, and how it can best be recre-
ated (United States Patent and Trademark Ofice, 2008). In the United States (US), 
patent rights are constitutional in nature and were designed to encourage innovation. 
Article I of the US Constitution provides that: “[t]he Congress shall have power . . . 
[t]o promote the progress of science and useful arts, by securing for limited times to 
authors and inventors the exclusive right to their respective writings and discover-
ies.”7 In the EU, patents by and large follow a similar path to the US system, with 
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FIGURE 12.2
Intellectual property rights as part of the product legal life cycle.
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the additional challenge of making sure one can secure a European-wide patent, to 
avoid having to go through 27 different legal systems.
Patents have been described as “monopoly” rights because they totally exclude 
others from unlicensed use of the idea or invention during the patent period.8 They are 
unusual because in most other areas of the law, governments seek to limit or elimi-
nate monopolies. However, the main objective of patent law is to provide an incen-
tive to reward innovation and facilitate its prompt use. Thus, in exchange for publicly 
explaining an invention, a period of exclusivity is granted (Smith and Parr, 2005).9
The multidisciplinary nature of nanotechnology often makes patenting issues dif-
icult to manage. The science of nanotechnology encompasses everything from phar-
maceuticals and medical devices to polymer additives to electronics. Nanotechnology 
has been described as an “enabling science” because it is an adjunct to so many 
existing research areas. Over the past decade, there has been an explosion of patents 
employing nanotechnology, leading to what is called a “patent thicket.” One com-
mentator found that 264 nanotechnology patents were granted in the US in 1998 and 
that number had increased to 1577 in 2004 (Matsuura, 2006). Another expert esti-
mated that there were approximately 4000 nanotechnology patents in the US by 2004 
(Miller et al., 2005).10 Yet another counted 7464 by the end of 2011.11 One thing is 
for certain, lawyers recognize the big business opportunities presented by nanotech-
nology. Currently, 53 US attorneys on Martindale–Hubbell list nanotechnology IP as 
a specialty. The number is sure to grow.
The three primary requirements12 for patentability are novelty (Matsuura, 2006),13 
utility (Miller et  al., 2005; Matsuura, 2006),14 and nonobviousness (Matsuura, 
2006).15 Novelty and utility are largely self-explanatory concepts. Traditionally, 
“obviousness” has focused on differences between the claimed invention and what 
9  Woodbridge v. United States, 263 US 50 (1923), available at http://supreme.justia.com/us/263/50/
case.html; see also Smith and Parr (2005) (quoting Burge (1984)): “While the right of ownership in 
most personally property is a positive right, the right of ownership in a patent is a negative right. It is 
the negative right to exclude others from making, using or selling the patented invention.”
10  Regarding search terms, Miller et al. (2005) reported that using different terms “can lead to num-
bers anywhere from 1100 to 17,000—depending on the search terms used.”
11  J. Steven Rutt, Cleantech & Nano, “Nanotech Patent counting in 2011: Record Numbers, Slight 
Growth . . . Good Management,” http://www.nanocleantechblog.com/2011/12/27/nanotech-patent-
counting-in-2011-record-numbers-slight-growth-good-management (last accessed 21.12.12).
12  See, e.g., Bonito Boats, Inc. v. Thundercraft Boats, Inc., 489 U.S. 141, 149-150 109 S.Ct. 971, 977 
(1989), available at http://supreme.justia.com/cases/federal/us/489/141 (last accessed 21.12.12).
13  35 U.S.C. §102 requires novelty as a condition for patentability. This largely requires the invention 
to be unknown, unused, unpublished, and/or unpatented and without prior patent applications.
14  35 U.S.C. §103 (2002). “The basic quid pro quo contemplated by the federal Constitution and 
Congress for granting a patent monopoly is the beneit derived by the public from an invention with 
substantial utility.” Brenner v. Manson, 383 US 519 (1966).
15  35 U.S.C. §103. Ramirez v. Perez, 457 F. 2d 267 (5th Cir. 1972), available at http://bulk.resource 
.org/courts.gov/c/F2/457/457.F2d.267.71-2073.html; Graham v. John Deere Co., 383 US 1 (1966), 
available at http://supreme.justia.com/us/383/1/case.html.
8  Zenith Radio Corp. v. Hazeltine Research, Inc., 395 US 100, 135 (1969), available at http://
supreme.justia.com/us/395/100/case.html (citing Bement v. National Harrow Co., 186 US 70 (1902)).
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the prior art/literature reveals and is often the most dificult requirement to satisfy.16 
A patent cannot be granted if “the subject matter as a whole would have been obvi-
ous at the time the invention was made to a person having ordinary skill in the art.”17 
Reducing the size of something—with no other improvement—has traditionally 
been found to be nonobvious.18 Accordingly, nanoscale inventions must show some 
novel or new property in order to be patentable. Simply shrinking something to the 
nanoscale is generally insuficient (Miller et al., 2005; Troilo, 2005).
Additionally, naturally occurring materials19 are not patentable (Dunens et  al., 
2008). Several IP law commentators have questioned whether and to what extent 
this general rule is applicable to nanoscale materials (Dunens et al., 2008).20 The key 
question is whether something new is being created by nanoscale science or whether 
the increasing sophistication and magniication of scanning and tunneling micro-
scopes is simply allowing scientists to see what was already there in new and greater 
detail. Certain crude fullerenes and nanotubes have been found to occur naturally. 
Nanoparticles appear in clay and soil and are mined/harvested for use because of lower 
cost. Are some or all nanoscale materials naturally occurring, and hence unpatentable?
Because the area of nanotechnology patents is growing so quickly and pre-
sents unique IP issues, many have questioned whether private IP attorneys, and 
more importantly examiners inside the US Patent and Trademark Ofice (USPTO), 
have suficient knowledge and expertise to make and/or evaluate patent applications 
(Bawa, 2004; O’Neill, 2007). The USPTO took some steps to address this issue when 
it created its “Class 977—Nanotechnology” cross-reference art collection in 2005. 
Similarly, the European Patent Ofice in 2003 set up a nanotechnology working group 
and started using “Y01N” tags to label nanotechnology in EPO databases.
Class 977 is a cross-reference collection; patents are irst placed in other cat-
egories and then provided a secondary nanotechnology classiication. The Class 
only includes engineered nanoscale materials, not incidental or natural ones. By 
June 2006, there were 4800 patents in Class 977. By the end of 2011, the number 
had grown to 7464. The Class employs examiners from many different backgrounds. 
One estimate places the number of USPTO examiners used to assist with Class 977 
at approximately 300 (Mouttet, 2005). The Class is designed to help examiners and 
attorneys search the prior art/literature for nanotechnology patents which would be 
otherwise scattered through numerous classes.
Once a company has protected its invention by obtaining a patent, it can proceed 
to commercialize its concept. Some companies—fewer and fewer these days—take 
an idea from inception completely through the manufacturing stage and into the 
16  Graham v. John Deere Co. of Kansas City, 383 US 1 (1996), available at http://supreme.justia.com/
us/383/1/case.html.
17  35 U.S.C. §103.
18  See, e.g., Premier Mach. Co. v. Freeman, 84 F.2d 425, 427 (1st Cir. 1936).
19  See, e.g., Bilski v. Kappos, 130 S.Ct. 3218, 3225, available at http://supreme.justia.com/cases/ 
federal/us/561/08-964 (last accessed 21.12.12).
20  Dunens et al. (2008, p. 31), citing Diamond v. Chakrabarty, 447 US 303, 309 (1980), have stated 
that “[t]he laws of nature, physical phenomena, and abstract ideas have been held not patentable.”
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marketplace itself. More likely is that a company will sell its patented ideas to another 
company outright or perhaps sell it the right to use the patent for some speciied dura-
tion and/or speciic purpose. The right to use the patent to the exclusion of all others 
is known as an “exclusive license.”21 The right to use the patent for a limited time or 
purpose at the same time as others use it is a “nonexclusive license.”22
While technology licensing is not unique to nanotechnology, it does present some 
novel issues in this context. Counsel retained for licensing purposes must not only 
know the ins and outs of the commercial law upon which the license itself is based 
(which is essentially a form of contract), he or she must also be intimately famil-
iar with the speciic subield of nanotechnology covered by the patent in question. 
Without such specialized knowledge, it is virtually impossible to prepare a license 
that adequately protects the licensee’s interests. For example, counsel must be fully 
versed in nanotechnology terminology and nomenclature in order to make sure the 
license is not overly broad or ambiguous in any respect. Additionally, incorporating 
standards developed by international standards organizations where appropriate is 
another valuable service that a skilled legal practitioner can provide to a client seek-
ing to license nanotechnology IP. The use of widely accepted standards can bring 
clarity to otherwise complex licensing agreements.
12.2.1.2 Trademarks
A trademark is “any word, name, symbol or device or any combination thereof [used 
to] identify and distinguish . . . goods, including a unique product, from those manu-
factured or sold by others and to indicate the source of the goods” (Smith and Parr, 
2005, p. 38). If they are distinctive and are not easily confused with a previously reg-
istered mark, trademarks can be registered with the USPTO in order to help protect 
their unique commercial value (Miller et  al., 2005). Not all trademarks are consid-
ered distinctive. A trademark that is generic or merely descriptive cannot be registered 
with the USPTO under normal circumstances. Trademarks that are considered “arbi-
trary and fanciful” or “suggestive,” on the other hand, can be successfully registered 
which puts the world on formal notice of their ownership.
Once a trademark is registered by the USPTO, it must be maintained by ensuring 
that it is used in a proper manner by the holder and that potential trespassers are kept 
at bay. If not properly maintained, a trademark can lose its USPTO protected status 
(Miller et al., 2005).
Because the word “nano” is a catchy metric preix, many companies have placed 
the word “nano” with some other descriptive term and then claimed that the result 
is a brand or trademark. These types of “nano-marks” are ubiquitous, but businesses 
must understand that they are often unprotected by federal trademark law and indeed 
EU law because they are viewed as merely descriptive and are not truly distinctive 
(Du Mont, 2008). For example, the name “Nano Legal News” used for a legal journal 
could not be trademarked because it is merely descriptive. Adding the word “nano” in 
21  Textile Prods., Inc. v. Mead Corp, 134 F. 3d 1481, 1484 (Fed. Cir. 1998).
22  US Philips Corp. v. International Trade Comm., 424 F. 3d 1179, 1189 (Fed. Cir. 2005).
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front of “legal news” does not make it distinctive; it only describes the type of legal 
news provided. The touchstone in these instances is that where the term “nano” is a 
primary term used in the proposed trademark (rather than arbitrary, fanciful, or sug-
gestive), an examiner at the USPTO is likely to focus on the descriptive nature of the 
trademark and may reject its registration.23
12.2.1.3 Trade secrets
A trade secret is most commonly considered as “any information that can be used 
in the operation of a business or other enterprise and that is suficiently valuable 
and secret to afford an actual or potential economic advantage over others.”24 Most 
nanotechnology companies have information which they believe is trade secret 
and would be ruinous if released to their competitors. Trade secrets should be pro-
tected from disclosure by making anyone who has access to the information sign 
a conidentiality and non-disclosure agreement.25 This is not unique to the ield of 
nanotechnology. The agreement should be detailed and set forth the data and infor-
mation to be protected.
Once information is designated a trade secret, its secrecy must be vigilantly main-
tained otherwise it loses its legal protection. Evidence that information is indeed a pro-
tected trade secret and suficient efforts have been made to assure its protected status 
includes “restrictive covenants with employees,” “control on a need-to-know basis,” 
“segmentation of knowledge,” “control of speeches and technical articles,” “physical 
plant security,” “secure handling of visitors, vendors, and suppliers,” “ile and docu-
ment controls,” “careful control when all or portion of knowledge must be divulged to 
vendors or customers,” “use of trade secret legends on documents,” and existence of 
a “security ‘culture’ in which employees are aware of the need to protect intellectual 
property” (Smith and Parr, 2005, pp. 24–25; see also Cummings, 2008). It is important 
to maintain these indicia in order to keep trade secret status.26
23  See, e.g., Holmes Prods. Corp. v. Honeywell Consumer Prods., Serial No. 74/236, 945, 1999 TTAB 
LEXIS 597 (Trademark Trial and Appeal Board 1992); Cummins Engine Co. v. Continental Motors 
Corp., 359 F.2d 892 (US Ct. Cust. & Pat. App. 1966); In re: Fruit of the Earth, Inc., Serial No. 75/443, 
437, 2001 TTAB LEXIS 391 (Trademark Trial and Appeal Board 2001); In re: Manhattan Scientiic, 
Inc., Serial No. 75/447, 259, 2001 TTAB LEXIS 779 (Trademark Trial and Appeal Board 2001); and In 
re: Winield Locks, Inc., Serial No. 75/357, 114, 2000 TTAB LEXIS 446 (Trademark Trial and Appeal 
Board 2000). In re Microcell Corp.; Serial No. 75931410, 2005 TTAB LEXIS 295 (Trademark Trust 
and Appeal Board 2005) (“The test for determining whether a term or phrase is merely descriptive is 
whether the term or phrase immediately conveys information concerning a signiicant quality, charac-
teristic, function, ingredient, attribute, or feature of the product or service in connection with which it is 
used or is intended to be used.” (citations omitted)).
24  Restatement of the Law (Third), Unfair Competition §39 (1995), available at http://www.law 
.uconn.edu/homes/swilf/ip/statutes/restatement38.htm, see also, Aronson v. Quick Point Pencil, 
Co., 440 U.S. 257, 266 (1979), available at http://supreme.justia.com/cases/federal/us/440/257 (last 
accessed 21.12.12).
25  See, e.g., Intera Corporation v. Henderson, 428 F.3d 605, 609–610 (6th Cir. 2005), available at 
http://bulk.resource.org/courts.gov/c/F3/428/428.F3d.605.04-6081.html.
26  See, e.g., Taco Cabana Intern., Inc. v. Two Pesos, Inc., 932 F.2d 1113, 1123-1124 (5th Cir. 1991), avail-
able at http://law.justia.com/cases/federal/appellate-courts/F2/932/1113/289051 (last accessed 21.12.12).
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12.2.2 Workplace and occupational liability
Potential workplace and occupational liability is most prevalent at the manufacturing 
stage, but can occur at any time prior to the consumer stage. Occupational liability of 
some sort typically occurs when an employer, researcher, or a worker is injured in the 
workplace during the course of his or her employment. Fortunately, there is already 
a good base of existing information available to attorneys and EHS professionals 
attempting to limit a nanotechnology company’s potential workplace and occupa-
tional liability and protect its workers (Figure 12.3).
12.2.2.1 NIOSH, OSHA, and EU equivalents
Since 2004, the National Institute for Occupational Safety and Health (NIOSH) has 
given a considerable amount of attention to nanotechnology workplace safety issues. 
NIOSH has published three primary nano-related documents: “Approaches to Safe 
Nanotechnology: An Information Exchange with NIOSH,” “Progress Towards Safe 
Nanotechnology in the Workplace: A Report from the NIOSH Nanotechnology 
Research Center,” and “Strategic Plan for NIOSH Nanotechnology Research and 
Guidance, Filling the Knowledge Gaps.” The Occupational Safety and Health 
Administration has taken the position that its existing standards are applicable to 
nanoscale materials handled by workplace employees.
By way of background, NIOSH theorizes that it is possible that an inordinate num-
ber of inhaled nanoparticles may deposit in deeper areas of the human respiratory tract 
when compared to their larger counterparts. If these nanoparticles are deposited deep 
in the lung, NIOSH is concerned that they may be able to translocate throughout the 
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body via the bloodstream. Once in the bloodstream, NIOSH is also concerned that engi-
neered nanoparticles may be able to cross cell membranes and the blood–brain barrier 
(Centers for Disease Control and Prevention, 2006). NIOSH recognizes that airborne or 
“free” nanoparticles present the greatest exposure risks. On the other hand, nanoparti-
cles conined in a solid matrix or inished component are unlikely to present signiicant 
exposures unless those substances are somehow degraded.
According to NIOSH, engineered nanoscale materials present a unique work-
place balancing act. Speciically, the scientiic data and information available regard-
ing the potential EHS risks of engineered nanoscale materials are new and relatively 
limited. Additionally, scientiic data on the possible health effects in exposed work-
ers are largely unavailable. These new, limited, and unavailable data present NIOSH 
and nanotechnology manufacturers with the dilemma of how to best protect workers 
when the full extent of risk is unknown (Centers for Disease Control and Prevention, 
2006).
At the same time, NIOSH recognizes that the same novel characteristics of engi-
neered nanoscale materials that make them attractive for research, development, and 
commercialization purposes may also mean that their fundamental toxicity character-
istics differ from their bulk counterparts. Thus, commercialization must be balanced 
against preventing reasonably foreseeable injuries which might accompany any expo-
sure to engineered nanoscale materials in the workplace.
While acknowledging that more research is necessary in almost every aspect touch-
ing workplace safety, NIOSH has published some general guidelines for companies 
working with nanoscale materials (Centers for Disease Control and Prevention, 2006). 
These recommendations should be of prime concern to attorneys and EHS specialists 
advising their clients in the area. NIOSH’s speciic recommendations include:
● employing interim occupational exposure measures until the risks presented by 
engineered nanoscale materials are better understood;
● limiting exposure to nanoscale materials in gaseous phases or powders;
● monitoring the amount of material being used, the duration of use, and particle 
size;
● wearing adequate skin and inhalation protection devices when handling 
engineered nanoscale materials;
● completely enclosing any pouring or mixing operations involving engineered 
nanoscale materials;
● using traditional environmental engineering controls such as dust collection 
systems, fume hoods, and vacuums;
● avoiding cleanup techniques for workplace surfaces in facilities using 
engineered nanoscale materials that are likely to disperse materials such as dry 
wiping or cleaning with blasts of compressed air;
● using high eficiency particulate air (HEPA)-certiied respiratory devices;
● preventing the consumption of food and beverages in the nano-workplace;
● providing clothes changing and showering facilities;
● considering undertaking baseline worker health surveillance efforts.
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NIOSH has also published a formal research plan to close the information gaps 
it has identiied regarding possible workplace exposure, as well as general safety 
guidelines for employers and employees working with engineered nanoscale materi-
als (Centers for Disease Control and Prevention, 2008). NIOSH is also conducting its 
own primary workplace exposure and material toxicity research and sponsors a valu-
able program through which it conducts ield studies of nanomanufacturing facilities 
in order to gather exposure data and to help employers make their work areas as safe 
as possible for workers using engineered nanoscale materials (National Institute for 
Occupational Safety and Health, 2009).
Finally, NIOSH has issued recommended exposure limits (REL) for certain 
nanoscale materials. For example, the draft NIOSH REL for carbon nanotubes is 
7 µg/m3. While these RELs do not have the force of law, they are becoming default 
safety standards and may eventually make their way into formal regulations.
More recently, CPSC (Consumer Product Safety Commission) formally 
announced a new agreement it has reached with US Environmental Protection 
Agency (EPA) to jointly assess the potential EHS risks posed by the use of nanoscale 
materials in consumer products and the chemical substances used in the manufacture. 
These added resources should add to CPSC’s capabilities in this area.
In the EU, concerns are of course similar to those in the US, albeit the regulatory 
structure is quite different. The most relevant law is Framework Directive 89/391/
EEC “on the introduction of measures to encourage improvements in the safety and 
health of workers,”27 which has a variety of so-called daughter Directives some of 
which may be relevant for nanoparticles. However, neither in the framework Directive 
nor in the daughter Directives, are there as yet any speciic provisions on nanotech-
nologies, instead contenting themselves with generic provisions such as that employ-
ers need to ensure the safety of their workers and organize relevant data gathering 
and consultation to that effect. Moreover, the European Agency for Safety and Health 
at Work, commonly known as “OSHA,” does not have the kind of regulatory pow-
ers which NIOSH has in the US. In the EU, this role is fulilled by agencies at the 
national level in conjuncture with the European Commission. As a result of restric-
tions under European law, agencies cannot be tasked with duties which are truly 
executive, making them, like OSHA, more of a data clearing house and advisory 
organization. Moreover, under the aforementioned framework directive, Member 
States may take measures that go beyond what the EU itself has ruled—although in 
the case of nanotechnology, none of them have done so.
It should be noted that the European Commission is planning to assess the need to 
review EU legislation on occupational health and safety in the course of 2014. Such 
assessment will be based on the results of two different ongoing work streams at EU 
level: (i) a study commissioned in 2011, aiming to establish the potential impact of 
nanomaterials and nanotechnology at the workplace and to evaluate the scope and 
requirements of possible modiications of relevant EU safety and health at work leg-
islation and (ii) a draft opinion on risk assessment and management of nanomaterials 
27  Oficial Journal [1989] L183.
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at the workplace, prepared by a Nano subgroup operating under the so-called EU 
Advisory Committee on Safety and Health at Work.
Despite the current lack of speciic EU legislative provisions relating to the 
health and safety of workers exposed to nanomaterials, a number of organizations 
and industries have opted to adopt relevant voluntary measures (e.g., codes of con-
duct) (German Chemical Industry Association [VCI], 2007).28 OSHA maintains an 
online database of company Good Practice examples relating to workplace man-
agement of manufactured nanomaterials, which cover a wide range of industries in 
various EU Member States.29
12.2.3 Worker’s compensation
Under traditional US workplace and occupational liability laws, an employer is 
required to provide worker compensation insurance to cover possible injuries to 
employees resulting from their employment. These laws are applicable in the event 
of any workplace injury resulting from exposure to engineered nanoscale materials. 
Thus, rather than sue an employer for a workplace injury, the worker is compen-
sated out of an insurance-type fund.
Workers’ compensation laws vary from state to state. Every nanotechnology 
company should make itself knowledgeable concerning the speciic state laws gov-
erning the operation of its facilities. Typically, an injured worker submits a claim to 
his or her employer which is substantiated by a treating doctor’s medical records. 
The insurer then investigates the claim to determine whether the employment and 
injury are legitimate, the injury was work related, and that the work in question was 
a substantial factor leading to the injury. Usually, a worker’s compensation claim 
must be iled within a speciied time of the alleged injury—6 months to 3 years 
depending upon the state—and the employer must be notiied of the injury during 
the employee’s period of employment.
Workers’ compensation payments typically cover lost wages and medical treat-
ment. Additionally, if a worker suffers a permanent injury, he or she can receive a 
lump sum payment for the disability under some States workers’ compensation stat-
utes. The system is “no fault” in that an employee does not have to show or allege 
that the employer acted negligently or did something wrong.30 A simple “on the job 
injury” is enough. On the other hand, the worker himself may have done something 
inadvertently to cause his or her own injury. Compensation is still allowed under work-
ers’ compensation laws under such circumstances because negligence is not an issue.31
28  See, e.g., the German Chemical Industry Association’s (VCI). Guidance for Handling and Use 
of Nanomaterials at the Workplace, available at https://www.vci.de/Services/Leitfaeden/Seiten/
Guidance-for-Handling-and-Use-of-Nanomaterials-at-the-Workplace.aspx.
29  Available at: https://osha.europa.eu/en/practical-solutions/case-studies/index_html/practical-solution? 
SearchableText=&is_search_expanded=True&getRemoteLanguage=en&keywords%3Alist=nano 
technology&nace%3Adefault=&multilingual_thesaurus%3Adefault=&submit=Search.
30  See, e.g., Alaska Packers Ass’n v. Industrial Acc. Com’n, 294 US 532 (1935).
31  See, e.g., New York Cent. R. Co. v. White, 243 US 188 (1917).
280 CHAPTER 12 A Nanotechnology Legal Framework
Many workers’ compensation statutes provide the exclusive remedy for workers 
injured on the job and do not allow workers to sue employers or co-workers.32 Thus, 
in many states an injured worker can receive worker’s compensation beneits, but then 
cannot turn around and sue the employer for his or her injuries.33 There are, naturally, 
exceptions to this rule including intentional torts.
Much like in the US, the European system for worker’s compensation and health-
care cover is organized at the national (compared with state) level, the EU not having 
much of a formal role to play in this policy area. Cover is typically more generous 
than in the US, although it is impossible to generalize on this issue.
With studies reporting toxicity in high doses and under speciic circumstances, 
and for speciied nanoscale materials, it is clear that employers must no longer 
assume that nanoparticles are always going to be able to be handled in the same way 
as their larger cousins. While lack of speciic data prevents employers from rolling 
out exact measures to deal with nanotechnologies, there would seem to be an increas-
ing relevance in making sure that a number of basic precautions are taken. This would 
include measurement and detection of nanoparticles in the workplace.
12.2.4 Intentional workplace torts
In some narrow cases, workers’ compensation statutes may allow an injured employee 
to sue an employer even if he or she irst collects worker’s compensation when the 
law deems the injury to be “intentionally” caused by the employer. In these limited 
instances, “intentional” means: (i) knowledge by the employer of the existence of a 
dangerous employment condition that rises above the general hazards of standard 
employment; (ii) knowledge by the employer that an injury is substantially certain 
to occur if the employee is subjected to the condition; and (iii) the employer requires 
the employee to continue to perform the task despite such knowledge. “Requires” can 
often be inferred from policies and procedures and need not be a direct command or 
instruction.34 “Mere knowledge and appreciation of a risk—something short of sub-
stantial certainty—is not intent.”35 Mere recklessness is also insuficient. This is a 
very dificult legal standard to meet, but because of potential punitive damages based 
on intentional conduct, such lawsuits are not infrequent, especially when the alleged 
injury is severe or other employees have suffered the same or similar injury.
To reduce exposure to this type of liability, nanotechnology companies must 
ensure that they consistently monitor the most up-to-date scientiic literature regard-
ing the potential exposure risks posed by any engineered nanoscale material used in 
the workplace. Eventually, enough scientiic literature may accumulate to allow a 
creative plaintiff’s attorney to argue that an employer “knew” the potential EHS risks 
34  See, e.g., Kerg v. Atlantic Food and Die Co., 892 N.E.2d 481, 485 (Oh. 8th Dist. 2008); Russell v. 
Lexis-Nexis, 2007 WL 949520 (Ohio App. 2 Dist. 2007).
35  See, e.g., Kerg v. Atlantic Food and Die Co., 892 N.E.2d 481, 485 (Oh. 8th Dist. 2008); Russell v. 
Lexis-Nexis, 2007 WL 949520 (Ohio App. 2 Dist. 2007).
32  See, e.g., US v. Demko, 385 US 149 (1966).
33  See, e.g., Blankenship v. Cincinnati Milacrom Chem., Inc., 433 N.E.2d 572 (Oh. 1982).
28112.2 Legal issues
(or even consciously avoided such knowledge). Once such knowledge is established, 
a plaintiff’s attorney will typically be able to locate some alleged defect in the com-
pany’s occupational hygiene process and then attempt to link the defect to his client’s 
purported inhalation or dermal exposure injury.
12.2.5 Commercial and contractual liability
Commercial and contractual liability is most prevalent in the transitions from the 
supplier stage to the manufacturing stage and from the manufacturing stage to the 
intermediate use or consumer stage. Of all the potential legal risks confronted by a 
nanotechnology company, it is the easiest to manage (Figure 12.4).
A contract is an agreement, obligation, or legal tie by which a party binds itself or 
becomes bound, expressly or implicitly, to pay a sum of money or to perform or omit 
to do some certain act or thing.36 It has also been deined as a set of promises for the 
breach of which the law gives a remedy, or the performance of which the law in some 
36  17A Am Jur 2d §1 (2004); Norfolk and Western Ry. Co. v. American Train Dispatchers Ass’n, 499 
US 117 (1991).
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way recognizes a duty.37 Exact deinitions differ in the EU, however, the basic idea 
remains the same.
Despite this legal mumbo jumbo, most nanotechnology business people already 
intuitively know what they want out of their business contracts and which areas are 
most important to them. There are, of course, an almost ininite different type of con-
tracts used for different purposes: employment agreements, conidentiality agreements, 
supply agreements, service agreements, leases, purchase and sale agreements, inanc-
ing, stock purchase agreements, government contracts, construction agreements, surety 
agreements, insurance contracts, guarantees, agency agreements, franchise, distribu-
tion, and joint development agreements, manufacturing agreements, master services 
contracts, and technology licensing agreements . . . you get the idea. Any or all of 
these contracts may involve nanotechnology businesses.
Some general considerations all nanotechnology businesses should keep in mind 
are that certain contracts must be in writing to be enforceable; contracts are gener-
ally construed against their drafter (thus it is important for a business to make sure 
the contract says exactly what it wants)38; courts endeavor to give contracts a reason-
able, fair, and practical construction39; and while the language of contract is normally 
given its ordinary meaning, ambiguity, and vagueness often require judicial interpreta-
tion.40 Additionally, businesses should be aware of the effect of prior negotiations and 
oral agreements on entering into a formal written contact.41 Further, because laws vary 
from state to state, a nanotechnology business must make sure it avails itself of the most 
favorable applicable law and consider including an alternative dispute resolution clause 
to limit potential legal costs in the event of a future dispute. Attorney’s fees provisions 
and legal forum selection clauses42 should also be considered to make sure a company 
ends up in the most favorable court in the event of a dispute.
12.2.6 Government regulation
Nanotechnology-speciic regulation must be carefully and thoroughly considered by 
every nanotechnology business. Nanospeciic regulation has been steadily accumulat-
ing in the course of the past few years and will, in all probability, continue to do so. As 
nanotechnology progresses and matures, businesses will increasingly ind that poten-
tial regulation may be prevalent in all stages of the nanotechnology legal product life 
cycle, especially in the supply, manufacturing, and disposal stages.
In the US, federal regulation of engineered nanoscale materials is most likely to 
take place through the EPA, the Food and Drug Administration (FDA) and the CPSC. 
Workplace issues involving NIOSH and OSHA are discussed above. In the EU, regu-
latory authority is much more centralized. While there are a wide variety of agencies 
and committees which play an important preparatory role, it is always the European 
38  See, e.g., Mastrobuono v. Shearson Lehman Hutton, Inc., 514 US 52 (1995).
39  See, e.g., Giove v. Department of Trans., 230 F.3d 1333 (Fed. Cir. 2000).
40  See, e.g., Republican Nat. Committee v. Taylor, 299 F.3d 887 (D.C. Cir. 2002).
41  See, e.g., Lanier Professional Services, Inc. v. Ricci, 192 F.3d 1 (1st Cir. 1999).
42  See, e.g., Stephen A. Goldberg Co. v. Remsen Partners Ltd., 170 F.3d 191 (D.C. Cir. 1999).
37  Restatement Second, Contracts §1.
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Commission, together with the European Parliament and the Council of Ministers, 
which prepares the actual regulation (Figure 12.5).
In the EU, the increasing number of speciic provisions for nanomaterials 
inserted in EU legal instruments, as well as guidance and other technical docu-
ments, has alarmed the European Commission with regard to the need to ensure the 
use of harmonized terminology. As a irst step to that direction, a Recommendation 
(European Commission, 2011a) on the deinition of nanomaterial has been 
adopted.43 According to it:
‘Nanomaterial’ means a natural, incidental or manufactured material contain-
ing particles, in an unbound state or as an aggregate or as an agglomerate and 
where, for 50% or more of the particles in the number size distribution, one or 
more external dimensions is in the size range 1 nm–100 nm.44
In speciic cases and where warranted by concerns for the environment, 
health, safety or competitiveness the number size distribution threshold of 50% 
may be replaced by a threshold between 1% and 50%.
By derogation [. . .], fullerenes, graphene lakes and single wall carbon 
nanotubes with one or more external dimensions below 1 nm should be consid-
ered as nanomaterials.
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43  Commission Recommendation of 18 October 2011 on the deinition of nanomaterial, OJ L 275/38, 
20.10.2011.
44  The Recommendation clariies that, where possible and requested in speciic legislation, the volume-
speciic surface area may be used to identify a potential nanomaterial. However, as there may be discrep-
ancies between the measurement of the speciic surface area and the number size distribution, the results 
of the number size distribution should always be the ones to prevail (i.e., the speciic surface area should 
not be used to demonstrate that a material is not a nanomaterial).
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The European Commission expects to primarily use the above deinition in new 
or revised legislative instruments, in order to identify materials for which speciic 
provisions may apply (e.g., as explained further below, the deinition has already 
been incorporated in the biocides legislation, while the adaptation of the deinition 
in the cosmetics legislation is currently in progress).45 The European Commission 
has clariied, however, that this does not suggest that speciic legislation needs to 
apply to all nanomaterials, or that no legislation may be adopted in the future to 
cover materials which fall outside the deinition’s scope. When adopting speciic 
legislative provisions on nanomaterials, the European Commission remains free 
to add further qualiiers to the above deinition after taking into account the sector 
concerned (e.g., in the pharmaceutical sector, nanoscale refers to a broader range 
than 1–100 nm).
With a view to ensuring a certain level of consistency in nanotechnology-
related activities taking place across the EU market (be them legislative or not), the 
European Commission has invited EU Member States, EU agencies, and economic 
operators to use the term “nanomaterial” as deined in its Recommendation. The 
European Commission expects to revisit the deinition periodically, not only in light 
of a number of lingering methodology issues and questions of scope but also due 
to the rapid evolution of the nanotechnology sector. The irst review is planned for 
2014 and will particularly focus on the number size distribution threshold.
12.2.6.1 Consumer product safety
In the US, the CPSC is tasked with protecting the public against unreasonable risk 
of injury associated with consumer products.46 A consumer product is an “article 
or component thereof used for the personal use, consumption or enjoyment of con-
sumers.”47 It does not include tobacco, motor vehicles, pesticides, irearms, air-
craft, boats, drugs, medical devices, cosmetics, or food, which are all regulated by 
other federal entities. The CPSC has broad powers to issue new safety standards, 
require product labels and warnings, require detailed written instructions, or even 
completely ban a product if it inds that it poses an unreasonable risk of injury to 
consumers.48 Under the CPSC’s statutory authority, a new consumer product rule, 
however, cannot be promulgated unless it is irst determined to be “reasonably nec-
essary to eliminate or reduce an unreasonable risk of injury associated with such 
product.”49 Additionally, the irst step in any CPSC restriction is the application of 
existing voluntary standards, then mandatory standards if voluntary standards are 
46  Consumer Product Safety Act, 15 U.S.C. §2051(b)(1) (2007), available at http://www.herc.org/
library/cpsa.pdf.
47  Consumer Product Safety Act, 15 U.S.C. §2052(a)(1) (2007), available at http://www.herc.org/
library/cpsa.pdf.
48  Consumer Product Safety Act, 15 U.S.C. §2056(a)(1)–(2) and 2057 (2007), available at http://
www.herc.org/library/cpsa.pdf.
49  Consumer Product Safety Act, 15 U.S.C. §2058(f)(3)(A)–(F) (2007), available at http://www.herc 
.org/library/cpsa.pdf.
45  See also Bowman et al. (2010b).
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inadequate, and inally resort to a product ban or labeling or other remedial meas-
ure which are used if certain legal and factual indings are met.
The key to the process is that the CPSC must select the least burdensome 
requirement to prevent or adequately reduce the speciic, targeted risk of injury. 
Beyond rule making power, the CPSC also has the legal authority to bring a law-
suit to seize dangerous products or prevent their manufacturer or distribution if 
they present an imminently hazardous consumer risk. An “imminent risk” means 
a product that presents an “imminent and unreasonable risk of death, serious ill-
ness, or severe personal injury.”50 The CPSC also has complete legal authority to 
require manufacturers to recall or repair defective products and has access to civil 
and criminal penalties for noncompliance.
All existing consumer products containing engineered nanoscale materials are 
subject to existing consumer product safety laws. The jurisdiction and legal author-
ity of the CPSC is more than broad enough to cover any potential risk posed by 
the use of nanoscale materials in consumer products (Innovation Society, 2007). 
Currently, there is no substantial evidence supporting the theory that the use of 
engineered nanoscale materials in existing consumer products poses any EHS dan-
gers. This may change in the future.
While legal authority is not a major obstacle for the CPSC in dealing with poten-
tial nano-related EHS risks, funding and staff are insuficient. As of March 2007, the 
CPSC had only spent US$20,000 on nanotechnology EHS research which primarily 
consisted of a literature review.51 Appropriations for the CPSC for iscal years 2009 
and 2010 for nanotechnology EHS issues, however, total approximately US$1 mil-
lion each year.52 In 2007, the Commissioner of the CPSC made a telling statement:
other agencies are asking for, and getting, millions of dollars for research in this 
area. Given the many products already on the market using nanotechnology, 
from computer chips to Docker pants, I do not think it will be too long before 
the agency is asked to assess the risks of nanotechnology used in some consumer 
products under our jurisdiction. At this point in time we would be hard pressed 
to make such an assessment. We simply do not have the resources to get up to 
speed in this area.53
The EU does not have an agency along the lines of the CPSC. As in the US, 
many of the products which are exempt from the CPSC are regulated under spe-
ciic approval processes with relevant agencies acting in various advisory 
53  Statement of Commissioner Thomas H. Moore submitted to the Subcommittee on Consumer Affairs, 
Insurance, and Automotive Safety, Senate Committee on Commerce, Science, and Transportation, 7 (2007), 
available at www.cpsc.gov/pr/moore2007.pdf.
50  Consumer Product Safety Act, 15 U.S.C. §2061(a)(3) (2007), available at http://www.herc.org/
library/cpsa.pdf.
51  Statement of Commissioner Thomas H. Moore submitted to the Subcommittee on Consumer Affairs, 
Insurance, and Automotive Safety, Senate Committee on Commerce, Science, and Transportation, 
7 (2007), available at www.cpsc.gov/pr/moore2007.pdf.
52  CPSC Reform Act, §2663, http://thomas.loc.gov/cgi-bin/query/z?c110:S.2663 (last accessed 04.03.09).
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capacities. This includes food, drugs, and medical appliances (see below in Section 
12.2.6.2.8.1). Where no speciic agency with attached regulatory framework exists, 
EU law falls back on either general product safety laws which are a power of the 
Member States or on sector-speciic Directives without a speciic agency that has 
authority over them. Toys and the toys safety Directives are a case in point. With 
respect to general product liability, while the European product liability Directive54 
has been found to go further than merely minimum harmonization,55 the regime in 
practice leaves so much to the Member States than one wonders whether the extent 
of harmonization truly deserves anything else but the qualiication “minimum.” 
Indeed a large number of issues which one cannot but consider the core of liability 
considerations, such as causation, remoteness of damage, standard of proof, con-
tributory acts, assessment of damages, and discovery, are all left to the discretion 
of domestic law (Faigrieve, 2005). Hence to truly have an insight into how product 
liability law impacts on the development of new technologies, one would have to 
review all case law of the various Member States—or at least the key States. The 
danger of having 27 different liability regimes often is a strong incentive for the 
Commission to act on the basis of its powers for the preservation of the Internal 
Market: with manufacturers having to produce in accordance with agreed health, 
safety, and environment standards, the Internal Market may be safeguarded.
12.2.6.2 Environmental regulation
In the US, federal environmental regulation of engineered nanoscale materials is 
most likely to occur under the Toxic Substances Control Act (TSCA), the Federal 
Insecticide, Fungicide, and Rodenticide Act, the Resource Conservation and 
Recovery Act (RCRA), the Comprehensive Environmental Response Compensation 
and Liability Act (CERCLA), and other “traditional” environmental statutes which 
focus on “end of pipe” or “end of stack” emissions. Additionally, there is a slow but 
growing trend of local and state regulation. Government regulation is most likely to 
affect the manufacturing and disposal stages of the nanotechnology product legal 
life cycle. For most if not all of these various sectors, there are equivalent legal 
instruments in the EU, albeit with differing contents as we shall see below.
12.2.6.2.1 Toxic Substances Control Act
The TSCA is a comprehensive federal environmental regulatory scheme covering 
the manufacturing, distribution, sale, and use of all chemical substances. TSCA 
provides the US EPA with full legal authority to gather EHS information and to 
require research regarding chemical substances of potential concern.56 The manu-
facture of existing chemical substances is strictly controlled and regulated. The 
manufacture of new chemical substances can only occur after proper application 
56  Chemical Manufacturers Association v. EPA, 259 F.2d 977, 979 (D.C. Cir. 1988).
54  Directive 85/374 on the approximation of the laws, regulations, and administrative provisions of 
the Member States concerning liability for defective products (1985) OJ L210.
55  See the case-law of the European Court of Justice: Case C-183/00, Gonzalez Sanchez v. Medicina 
Asturiana SA (2002) ECR I-3901.
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and safety documentation and often only within certain limits and conditions 
imposed by EPA.57 There are strict civil and criminal penalties for TSCA viola-
tions, including injunctive relief and large inancial penalties.
12.2.6.2.1.1 New chemical substances One of the key questions regarding engi-
neered nanoscale materials under TSCA is whether they constitute new chemical 
substances and/or signiicant new uses of existing chemical substances for regula-
tory purposes. If an engineered nanoscale material falls into either of these catego-
ries, a manufacturer must submit a pre-manufacture notice and application to EPA 
substantiating the safety of the product given the proposed use.
In 2007, EPA published an issue paper explaining its treatment of engineered 
nanoscale materials under TSCA and whether it considered any or all of them new 
or existing chemical substances for regulatory purposes (Environmental Protection 
Agency, 2007). The EPA indicated that it does not consider all nanoscale materials to 
be new chemical substances just because of their diminutive size. Rather, a particular 
engineered nanoscale material must have a new and distinct molecular identity not 
shared with any other existing chemical substance on the TSCA inventory before it is 
considered a “new” chemical substance. EPA indicated that it was going to examine 
each nanoscale material in question on a case-by-case basis to determine whether it 
was in fact a new or existing chemical substance for purposes of TSCA and would 
make no blanket statements in this regard.
In October 2008, EPA issued a federal register notice reiterating its position that 
it would not treat all nanoscale materials as new chemical substances under TSCA 
(Environmental Protection Agency, 2008a). However, EPA also classiied car-
bon nanotubes as new and distinct chemical substances from graphite or other car-
bon allotropes previously listed on TSCA inventory and stated that they are subject 
to pre-manufacture notice and application requirements. EPA encouraged all carbon 
nanotube manufacturers to submit pre-manufacture notice applications under TSCA 
as quickly as possible and indicated that it would start enforcing its ruling regarding 
carbon nanotubes in March of 2009 (Environmental Protection Agency, 2008a). The 
EPA also recommended that companies in doubt as to whether their speciic engi-
neered nanoscale material constitutes a “new” chemical substance for TSCA purposes 
should submit a request for an inventory search to clarify the issue.
Beyond its TSCA guidance documents, thus far, EPA has entered into several 
consent orders under TSCA requiring the manufacturer to conduct 90-day inha-
lation animal studies to analyze the subchronic toxicity of the products in question 
(Ofice of Pollution Prevention and Toxics, 2008). The agency’s impetus for these 
consent orders was its lack of knowledge concerning their possible health effects on 
humans coupled with purported tests on analogous substances which showed poten-
tial toxicity concerns. Speciically, while EPA predicted poor human absorption of 
carbon nanotubes through all exposure routes, it expressed concern regarding possi-
ble lung irritation and exposure from analogous respirable, poorly soluble particles. 
Accordingly, EPA stated that there might be a potential risk to workers exposed to 
57  Toxic Substances Control Act, 15 U.S.C. §2604(a) (2007), available at http://epw.senate.gov/tsca.pdf.
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carbon nanotubes through inhalation and/or dermal exposure. The agency further 
noted a potential risk to the public from water and landill disposal or the incineration 
of carbon nanotubes.
Another consistent consent order requirement is the exclusion of any purposeful 
or predictable releases of the nanoscale material to water. While US EPA has shown 
some limited lexibility on this issue, businesses should be aware of the important 
impact that such a requirement could have on their business model.
Additional requirements imposed by US EPA are the use of NIOSH approved 
N100 respirators, impermeable gloves, and other protective gear in the workplace. 
Educating customers/processors about these requirements as well as retailed record 
keeping is also required.
12.2.6.2.1.2 Significant new uses of existing chemical substances Beyond “new” 
chemical substances, if EPA determines that a speciied use of an existing chemical 
substance constitutes a “signiicant new use” of that substance, pre-manufacture notice 
and approval requirements are also triggered. The relevant factors in determining 
whether a proposed use constitutes a signiicant new use are the projected volume of 
manufacturing and processing of the substance; the extent to which there are changes 
in the type or form of exposure resulting from the speciied use; whether there is an 
increase in the magnitude or duration of exposure from the proposed use; and the 
methods of manufacturing, processing, distributing, and disposing of the chemical sub-
stance.58 No factor is conclusive by itself. Some EHS advocates have lobbied EPA to 
issue a blanket rule stating that the use of all nanoscale materials constitutes “signii-
cant new use” of an existing substance under TSCA (Section of Environment, Energy, 
and Resources, American Bar Association, 2006). The agency, however, has indicated 
that it has no intent to issue a categorical signiicant new use rule for all nanoscale 
materials, rather it intends to examine them on a case-by-case basis considering the 
four above-referenced factors (Monica, 2007). However, a general nano-related pro-
posed Signiicant New Use Rule (SNUR) of some type was submitted to the Ofice of 
Management and Budget (OMB) in 2010 where it still currently resides. It is unknown 
when or whether the SNUR will ever be released from OMB and make its way into a 
proposed rule published for public comment.
Applying these factors, EPA has issued signiicant new use rules for two engi-
neered nanoscale materials used as additives in other chemical products as of the date 
of this text.59 The engineered nanoscale materials in question were siloxane-modiied 
silica nanoparticles and siloxane-modiied alumina nanoparticles. Each chemical sub-
stance was the subject of a pre-manufacture notice submission under TSCA which 
triggered EPA’s review. The agency made it clear that possible dermal and inhalation 
exposure to the substances was not anticipated under the uses set forth in the appli-
cations. The agency further declined to determine whether the substances actually 
posed unreasonable risks, but expressed concern that based on analogous materials, 
58  Toxic Substances Control Act, 15 U.S.C. §2604(a)(2) (2007), available at http://epw.senate.gov/tsca.pdf.
59  Signiicant New Use Rule on Certain Chemical Substances, 40 CFR §721.10119 (2008), available 
at http://edocket.access.gpo.gov/2008/E8-26409.htm.
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the engineered nanoscale materials in question might present inhalation and/or dermal 
penetration concerns. Accordingly, EPA’s signiicant new use rules required the man-
ufacturers to ensure that the materials were not used in occupational settings without 
the use of impervious gloves and NIOSH approved respirators. Additionally, the sig-
niicant new use rules prohibited the use of the substances in powder form.
12.2.6.2.2 Nanoscale Materials Stewardship Program
A signiicant part of EPA’s past efforts under TSCA to address the potential EHS con-
cerns accompanying the use of certain engineered nanoscale materials was focused 
on its Nanoscale Materials Stewardship Program (NMSP) which was created and 
implemented under TSCA (Environmental Protection Agency, 2008a). The NMSP 
was irst implemented in February 2008 and was designed to collect existing data 
from manufacturers of engineered nanoscale materials for later use in possible regula-
tion. While EPA has publicly stated that regulation is not the inevitable outcome of 
the NMSP, few nanotechnology companies believed otherwise.
The NMSP asked participants to submit information and data regarding their 
engineered nanoscale materials to EPA under two plan levels.
The irst, “basic” plan level sought data regarding existing material characteriza-
tion, hazard, use, potential exposure, and risk management practices. EPA believed 
this information should be readily available to most nanoscale material manufactur-
ers. As of December 2008, 29 companies had submitted basic information covering 
123 nanoscale materials under the “basic” plan level. The second, “in-depth” level of 
the NMSP asked companies to partner with each other and EPA to generate new data 
on speciic nanoscale materials of interest. This portion of the NMSP was projected to 
take several years to complete. As of December 2008, four companies had committed 
to working with EPA under the “in-depth” program.
In January 2009, EPA published an interim report on the successes and failures 
of its NMSP to date (Ofice of Pollution Prevention and Toxics, 2009). The agency 
admitted mixed results. On the one hand, EPA stated that “the program has sufi-
ciently advanced EPA’s knowledge and understanding to enable the agency to take 
further steps towards evaluating and, where appropriate, mitigating potential risks to 
health and the environment.” On the other hand, the agency noted that at least 90% of 
the existing nanoscale chemical substances which are commercially available were 
not reported under the program thus far. The report also found that “the low rate of 
engagement in the in-depth program suggests that most companies are not inclined to 
voluntarily test their nanoscale materials” (Ofice of Pollution Prevention and Toxics, 
2009, p. 27).
EPA was slated to issue a inal report on the NMSP in 2010, but none was forth-
coming. In any event, unless something surprising develops, it is dificult to imag-
ine that it will be possible to genuinely characterize the NMSP as successful.
12.2.6.2.3 REACH
As for the European counterpart for TSCA, the Regulation on the Registration, 
Evaluation, Authorization, and Restriction of Chemicals (REACH) (Regulation 
1907/2006) (European Commission, 2006) signaled a fundamental shift in the way in 
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which manufactured and imported chemical substances are regulated within the EU 
(Bowman and Van Calster, 2007a,b). REACH prohibits the manufacture or sale of 
any chemical substance in the EU that has not been registered with the agency. Unlike 
the previous EU chemical regulatory regime, which somewhat arbitrarily differenti-
ated between chemical substances on the basis of being “existing” or “new,” REACH 
creates a uniform regime for the registration of all substances. Registration is volume 
based with registration and risk assessment requirements dependent upon the mass 
of the chemical substance manufactured, imported, or produced by each manufac-
turer, importer, or producer (the registrant) each calendar year. As with the previous 
regime, REACH does not differentiate substances on the basis of their size, but rather 
on the basis of the substance’s Chemical Abstract Service (CAS) number. However, 
in light of the ultimately unsuccessful last minute attempt by Members of the 
Committee on the Environmental, Public Health, and Food Safety of the European 
Parliament to include speciic provisions on engineered nanoparticles (Committee on 
the Environment, Public Health and Food Safety of the European Parliament, 2006), 
uncertainty remains as to both certain aspects of the registration of nanoscale sub-
stances or substances in nanoform by the various registrants, as well as their treat-
ment by the regulator, the European Chemicals Agency (ECHA), as REACH is 
rolled out. Early on, review led to a removal of nanoparticles from the exemption of 
“naturally occurring substances,” such as carbon dioxide, and the Head of the ECHA 
announced, in June 2009 already, that the agency was likely to adapt speciic rules as 
to how nanoparticles are to be treated under REACH.
In this context, the ECHA made available a technical manual for registrants 
(2010) containing information on how to prepare their IUCLID dossiers for nano-
materials.60 In addition, the European Commission launched a comprehensive three-
tiered REACH Implementation Project on Nanomaterials (RIPoN) aiming to provide 
recommendations to the ECHA on key aspects of the implementation of REACH 
with regard to nanomaterials: (i) RIPoN 1 evaluated the applicability of existing 
guidance and developed speciic advice on how to establish the substance identity of 
nanomaterials; (ii) RIPoN 2 provided advice on how REACH information require-
ments on intrinsic properties of nanomaterials may be fulilled and outlined pos-
sible testing strategies; and (iii) RIPoN 3 developed advice on how to do exposure 
assessment and conduct hazard and risk characterisation for nanomaterials. On the 
basis of the recommendations contained in RIPoN 2 and RIPoN 3, the ECHA pub-
lished three new appendices (2012), updating a number of chapters of its Guidance 
on Information Requirements and Chemical Safety Assessment. Discussion among 
experts as to the RIPoN 1 recommendations is still ongoing and, therefore, these have 
not yet been transmitted to the ECHA for implementation.
Answering to concerns raised by a number of actors—including the European 
Parliament—regarding nanomaterial regulation, in its second regulatory review on 
nanomaterials (European Commission, 2012a), the European Commission reiterated 
60  IUCLID refers to the software application used by registrants to store data on chemicals and pre-
pare and submit dossiers.
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that REACH requirements are applicable to nanomaterials or nanoforms of sub-
stances, even if REACH contains no speciic legal provisions on them, and concluded 
that the REACH rules regarding the chemicals safety assessment, as well as the regis-
tration thresholds and timelines are appropriate for nanomaterials, too. However, the 
European Commission did acknowledge that uncertainty persists regarding certain 
aspects of REACH’s application when it comes to nanomaterials.
First, it noted that—due to the absence of relevant guidance and the wording of 
the REACH annexes—it is often the case that REACH registrations do not clearly 
indicate whether and which nanomaterial forms are covered by them, or how the 
information provided in them relates to nanomaterial forms, and do not specii-
cally address the safe use of the nanomaterials. In response to this, the European 
Commission committed to assess its regulatory options (e.g., potential amendments 
to some Annexes in the upcoming REACH review), on the basis of available infor-
mation on technical progress, including the RIPoNs and experience gained with the 
REACH registrations submitted to date.61
Second, it recognized that, since nanomaterials may be seen as forms of a given 
substance or as distinct substances, uncertainty prevails as to whether they are to be 
treated as new substances subject to REACH registration requirements. It announced 
that, in order to resolve such questions, the ECHA will provide relevant guidance. 
Due to the complicated nature of this problem, however, the European Commission 
expects that some lexibility will need to be shown in practice—the key issue being 
whether a registration covers the safe use of all forms of a given substance.
Given the clariication of terminology provided for in the European Commission’s 
Recommendation on a deinition for nanomaterial, as well as the update of 
REACH guidance regarding nanomaterials, it is expected that, by the 2013 dead-
line, the ECHA will receive a signiicant number of REACH registrations covering 
nanomaterials.
12.2.6.2.4 EU Biocides Regulation
In May 2012, the European Parliament and the European Union Council adopted 
a new regulation regarding the making available on the market and use of biocidal 
products,62 effective as of September 2013. The regulation marks the irst legislative 
instrument at EU level incorporating the deinition of “nanomaterial” as contained in 
the European Commission’s Recommendation (2011).
The Regulation provides for speciic approval and authorization requirements 
for nanomaterial-containing active substances and biocidal products, respectively. In 
so far as the approval of active substances is concerned, the Regulation clariies that 
such approval only covers nanomaterials if explicitly mentioned and, also, requires 
the provision of explanations regarding the scientiic appropriateness of the test meth-
ods used, including any technical adaptations or adjustments made to respond to the 
62  Regulation (EU) No 528/2012 of the European Parliament and of the Council concerning the mak-
ing available on the market and use of biocidal products, OJ L 167/1, 27.6.2012.
61  Such experience has been, inter alia, gained by a screening undertaking by the ECHA (2011), 
aimed at retrieving information on nanomaterials contained in the REACH registration database.
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materials’ speciic characteristics. With regard to the authorization of biocidal prod-
ucts, it is provided that when these contain nanomaterials they cannot beneit from the 
simpliied procedure laid down in the Regulation. Rather, their risk to human health, 
animal health, and the environment needs to be assessed separately. In line with the 
rules applicable for active substances, the scientiic appropriateness of the test meth-
ods used needs to be demonstrated.
Finally, the EU Biocides Regulation includes a requirement for all biocidal 
products which contain nanomaterials, as well as all articles treated with such prod-
ucts to be labeled, by clearly and indelibly listing on their labels the name of the 
nanomaterials they contain, as well as any speciic related risks, followed by 
the word “nano” in brackets.
12.2.6.2.5 Federal Insecticide, Fungicide, and Rodenticide Act
EPA has also levied a ine against one US nanotechnology company under the 
Federal Insecticide, Fungicide, and Rodenticide Act for marketing a product con-
taining engineered nanoscale materials using claims that the product killed germs 
and microbes (Environmental Protection Agency, 2008b). The company was based 
in California and was selling computer mice and keyboards coated with nanoscale 
silver claiming that the coatings killed germs and pathogens. Once such claims are 
made, the product is treated as a pesticide under the Federal Insecticide, Fungicide, 
and Rodenticide Act.63 At that point, any antimicrobial or germ killing claims must 
be substantiated through formal data submissions.64 Because the company made the 
claims without irst registering the product as a pesticide and/or submitting substan-
tiating data, EPA ined the company US$208,000.
There are numerous examples of products claiming to contain engineered 
nanoscale materials that are used to kill germs. Undoubtedly, EPA will similarly 
pursue these companies in the coming years.
12.2.6.2.6 Resource Conservation and Recovery Act
The disposal stage in the nanotechnology product legal life cycle also presents spe-
ciic issues regarding engineered nanoscale materials. The primary statutes in the 
US used to regulate the disposal of chemical substances are the RCRA and the 
CERCLA.
Under RCRA, the federal government regulates the disposal of both solid 
wastes and hazardous wastes. A substance can only be a hazardous waste if it is 
irst determined to be a “solid waste” under RCRA’s analysis. The disposal of “haz-
ardous wastes” is regulated much more strictly than the disposal of simple solid 
wastes. A solid waste is broadly deined as “any garbage, refuse, sludge from a 
waste treatment plant, water supply treatment plant, or air pollution control facility 
and any other discarded material, including solid, liquid, semi solid, or contained 
63  Federal Insecticide, Fungicide, and Rodenticide Act, 7 U.S.C. 136(mm)(1) (2008), available at 
http://www.law.cornell.edu/uscode/html/uscode07/usc_sup_01_7_10_6_20_II.html.
64  Federal Insecticide, Fungicide, and Rodenticide Act, 7 U.S.C. 136a(c) (2008), available at http://
www.law.cornell.edu/uscode/html/uscode07/usc_sup_01_7_10_6_20_II.html.
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65  Resource Conservation and Recovery Act, 42 U.S.C. §6903(27) (2002), available at http://www4 
.law.cornell.edu/uscode/42/ch82.html.
66  Resource Conservation and Recovery Act, 42 U.S.C. §6941 (2002), available at http://www4.law 
.cornell.edu/uscode/42/ch82.html.
67  Resource Conservation and Recovery Act, 42 U.S.C. §6922 (2000), available at http://www4.law 
.cornell.edu/uscode/42/ch82.html.
68  Available at: http://ec.europa.eu/environment/chemicals/nanotech/index.htm.
gaseous material resulting from industrial, commercial, mining, and agricultural 
operations, and from community activities.”65 Although no engineered nanoscale 
materials are currently speciically denominated solid wastes under RCRA, the def-
inition is broad enough to capture almost any such material. Solid wastes must be 
disposed of in strict conformance with state or regional waste plans and may only 
be disposed of at sanitary landills. These same requirements also apply to waste 
streams from manufacturing processes using engineered nanoscale materials.
Beyond solid wastes, a chemical substance may be labeled as a “hazardous 
waste” under RCRA if it is listed as a hazardous waste by EPA or if it is determined 
to be a characteristic “hazardous waste” that exhibits high ignitability, corrosivity, 
reactivity, or toxicity. Once a material is labeled as a hazardous waste, the material 
is tracked and permitted at all stages of the manufacturing, use, and disposal pro-
cess.66 Generators of hazardous wastes are required to keep detailed records from 
cradle to grave of the substance to ensure unintended releases and environmental 
contamination do not occur.67
In the EU, attention to the waste side of nanotechnologies has been slow in 
uptake, to say the least. The European Commission’s initial line on waste and nano-
technologies was that in light of the generic nature of the provisions of the rele-
vant Directives, the issues were at least covered in principle (2008). Pursuant to the 
European Parliament’s calls (2009) for a review of a number of aspects of the EU 
waste legislation in force with regard to nanomaterials (namely, the separate inclu-
sion of nanomaterials in the list of waste, the revision of the criteria for accepting 
waste in landills and the re-examination of emission limit values for waste incin-
eration), the European Commission commissioned (European Commission, 2011b) 
a study on the “Review of Environmental Legislation for the Regulatory Control 
of Nanomaterials,” as well as a study on the “Coherence of waste legislation.”68 
The conclusions of these studies largely reafirmed the stance that waste legisla-
tion addresses nanomaterials in principle, despite the fact that they revealed cer-
tain practical challenges. In this context, in its second regulatory review (European 
Commission, 2012a), the European Commission took the stance that even where it 
would be possible to exhibit the presence of nanomaterials in environmental waste, 
it would be technically dificult to separate or eliminate them in practice. It, there-
fore, is concluded that any potential risks would be best addressed upstream by the 
REACH and product legislation. However, it did not exclude the possibility to also 
adopt speciic downstream environmental legislation with regard to nanomaterials 
in the future.
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70  Directive 2004/35, OJ (2004) L143/56.
69  Comprehensive Environmental Response Compensation and Liability Act, 42 U.S.C. §9601(14), 
available at http://www4.law.cornell.edu/uscode/42/ch103.html.
12.2.6.2.7 Comprehensive Environmental Response Compensation 
and Liability Act
The CERCLA was irst enacted in 1980 with the purpose of cleaning up abandoned 
hazardous waste sites and assigning inancial responsibility. CERCLA applies very 
broadly to all “hazardous substances.” These include many substances on speciic 
lists created by EPA under the act, as well as other substances designated as hazard-
ous under other federal statutes.69 Because it is so broad, the deinition of “hazardous 
substance” under CERCLA covers virtually any engineered nanoscale material which 
might present EHS risks. Thus far, no engineered nanoscale materials have been 
treated as a hazardous substance under CERCLA simply because it is a nanoscale 
material. The biggest hurdle for applying CERCLA to a speciic engineered 
nanoscale material is determining whether it is deemed a hazardous substance under 
the statute. Once this scientiic determination is complete, CERCLA’s broad cleanup 
and cost apportionment provisions would apply (Section of Environment, Energy, and 
Resources, American Bar Association, 2006).
Perhaps the points nanotechnology companies should remember most about 
CERCLA are (i) it can be applied retroactively and (ii) liability can be joint, indi-
vidual, and several (Section of Environment, Energy, and Resources, American Bar 
Association, 2006). The irst point is important because even if engineered nanoscale 
materials are not considered a hazardous substance today, they may be considered as 
such tomorrow after the fact. The second point is important because a company with 
deep pockets may ind itself liable for the entire cleanup costs of a contaminated site 
even if it only contributed a relatively small amount of material to the site. This may 
be especially important years down the road when other companies which may have 
been primary contributors have been long dissolved.
The EU’s environmental liability regime70 imposes inter alia a strict liability 
regime for operators carrying out “hazardous” activities. They will be held strictly lia-
ble (i.e., there will be no need to show fault or negligence) for preventing or restoring 
any damage caused by those activities to land, water, and protected habitats and spe-
cies. It is noteworthy that the liability Directive does not cover “traditional damage,” 
i.e., personal injury and damage to personal goods and property—for such damage, 
the various liability regimes of the Member States apply.
“Hazardous activities” include manufacture, use, storage, processing, illing, 
release into the environment, and onsite transport of those substances which are clas-
siied as dangerous substances under the EU’s chemical legislation, referred to above. 
Hence there is a direct link between the classiication under the EU’s chemical policy 
and the ensuing liability.
Again, though, no speciic proviso has been made in the liability Directive for 
nanotechnology per se. Interestingly, at the time of negotiation of the Directive, the 
need was discussed for a speciic liability regime for GMOs, so as to address the 
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71  Environmental Protection Agency, Clean Air Act, History of the Clean Air Act, http://www.epa 
.gov/air/caa/caa_history.html (last accessed 03.04.09).
72  Clean Water Act, 33 U.S.C. §§1251(a), available at http://www.law.cornell.edu/uscode/html/
uscode33/usc_sup_01_33_10_26.html.
73  Safe Drinking Water Act, 42 U.S.C. §300g (1996), available at http://www.law.cornell.edu/
uscode/42/usc_sup_01_42_10_6A_20_XII_30_B.html.
uncertainty associated with the technology. Eventually, a consensus was found to 
leave GMOs within the standard remit of the Directive, pending further evaluation of 
the need to review this, by the Commission. Hence the Directive fully applies to GM 
technology, including the Directive’s defenses: if the release of the GMO was specii-
cally authorized or if it was not possible to anticipate the damaging effect on the basis 
of the state of scientiic and technical knowledge at the time, and if the operator was 
not negligent, all of which the operator has to prove, the competent authorities can 
exempt him/her from liability. For example, an operator would be negligent and thus 
liable if it does not follow the instructions provided by the GMO manufacturer or the 
competent authority authorizing the release (European Commission, 2004).
Similar considerations obviously apply to nanotechnology. In the current regulatory 
state, nanotechnological applications are not likely to have been speciically author-
ized, hence the defense one would have to raise relates to it not having been possible to 
anticipate the damaging effect on the basis of the scientiic knowledge at the time.
12.2.6.2.8 Traditional end of pipe environmental regulation
Finally, the applicability of “traditional” end of pipe and end of stack environmen-
tal regulations such as the Clean Air Act,71 Clean Water Act,72 Safe Drinking Water 
Act,73 and similar instruments in the EU to engineered nanoscale materials has been 
questioned because these regulations typically rely on mass determinants which may 
be inappropriate for engineered nanoscale materials. Simply put, number of par-
ticles and surface area may be more appropriate measures for the potential toxicity 
and hazards presented by certain engineered nanoscale materials rather than mass. 
Thus, traditional statutory triggers may be inappropriate. Whether these regulations 
need to be amended to encompass nanoscale materials is a subject of much debate. Of 
course, these statutes in their current form already apply to the bulk versions of cer-
tain nanoscale substances and there is no current substantial scientiic evidence that 
they should be treated otherwise.
12.2.6.2.8.1 Food and drug regulation The US FDA formed a Nanotechnology 
Task Force in August 2006 to assess the state of scientiic knowledge concern-
ing nano-related EHS concerns and evaluate the effectiveness of existing food and 
drug regulations to deal with any unique issues raised by nanotechnology (Food and 
Drug Administration, 2006). The Nanotechnology Task Force issued its irst written 
report in July 2007 which did not call for any new FDA regulatory authority to cover 
engineered nanoscale materials and concluded that the use of nanomaterials in FDA-
regulated products presents completely manageable challenges similar to those posed 
by other existing FDA-regulated products (Food and Drug Administration, 2007). 
However, FDA admitted that some of the unique properties exhibited by certain 
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engineered nanoscale materials could at some point create regulatory challenges and 
recommended developing guidance documents to clarify what information manufac-
turers should provide to FDA about nanotechnology products and the circumstances 
under which the regulatory status of certain products might change. As of May 2009, 
there is no intent to update, modify, or change the FDA’s report.
In the EU, the European Parliament, in its 2009 resolution74 on regulatory aspects 
of nanomaterials, called upon the European Commission to include nanospeciic provi-
sions in cosmetics and food legislation. The Resolution included some important regu-
latory constraints for the nanotechnologies sector, in particular for those incorporating 
nanomaterials in products. Most importantly, the text testiied to the increased readiness 
within the regulatory community to adopt targeted, nanospeciic regulation. Parliament 
employed its regulatory powers by proposing a much more proactive approach to 
nanoregulation in two areas: the review of cosmetics law in Europe (Bowman and Van 
Calster, 2008) and a similar update for so-called novel foods (Van Calster et al., 2008), 
where it proposed special treatment of nanoparticles and nanomaterials.75
Indeed, in the process of recasting the EU legislation on cosmetic products 
in 2009,76 the European Parliament secured the insertion of a number of speciic 
requirements for nanoparticle-containing cosmetic products.77
In particular, the Regulation prescribes that, in addition to the general notiica-
tion requirements applicable to cosmetic products placed on the EU market, nano-
material containing such products need to be notiied to the European Commission 
6 months prior to them being marketed in the EU—unless explicitly exempted from 
such obligation. In addition, a speciic safety assessment procedure is provided for 
cosmetic products which contain nanomaterials (European Commission, 2012b):78 in 
cases where the European Commission is concerned as to the safety of a nanomate-
rial, it is obliged to request the Scientiic Committee for Consumer Safety (SCCS) 
to provide an opinion on the safety of that nanomaterial in the relevant categories of 
cosmetic products and the reasonably foreseeable exposure conditions. In the sake 
of transparency, the indings of the SCCS are to be made publicly available and the 
European Commission is to compile by 2014 and regularly update thereafter a cata-
log of all nanomaterials used in cosmetic products placed on the market. Moreover, 
the European Commission, as of 2014, will be submitting an annual report to the 
European Parliament for the latter to be informed on developments on the use of 
nanomaterials in EU-marketed cosmetic products. Finally, the European Parliament 
74  European Parliament, Resolution of 24 April 2009 on regulatory aspects of nanomaterials, 
P6_TA(2009)0328.
75  European Parliament legislative resolution of 24 March 2009 on the proposal for a regulation on 
novel foods, A6-0512/2008.
76  Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic prod-
ucts, OJ L 342/59, 22.12.2009.
77  See also Bowman et al. (2010a) and Bowman and Van Calster (2008).
78  In 2012, the European Commission published a “Guidance on Nanomaterials in Cosmetics” to help 
the cosmetics industry comply with the speciic notiication and procedural requirements applicable 
to nanomaterial-containing products, available at http://ec.europa.eu/health/scientiic_committees/
consumer_safety/docs/sccs_s_005.pdf.
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insisted on and eventually secured the inclusion of a speciic labeling requirement for 
nanomaterials, according to which all ingredients in the form of nanomaterials need 
to be clearly indicated in the list of the cosmetic product’s ingredients and be fol-
lowed by the word “nano” in brackets.
With regard to the update of the novel foods legislation, according to the European 
Parliament’s proposal, nanospeciic test methods should be developed as a matter of 
urgency and nanomaterials present in food should be entered on a list of approved nano-
materials, for food contact materials accompanied by a limit on migration into or onto 
the food products contained in such packaging. This meant that until the development of 
such methods in practice, no such materials would be allowed in the market—in other 
words, a moratorium. The European Parliament also proposed to amend the deinition 
of a “novel food” to include food containing or consisting of “engineered nanomateri-
als,” and to have ingredients present in the form of nanomaterials clearly indicated in the 
list of ingredients. “Engineered nanomaterials” was deined by Parliament as:
any intentionally produced material that has one or more dimensions of the 
order of 100 nm or less or is composed of discrete functional parts, either inter-
nally or at the surface, many of which have one or more dimensions of the order 
of 100 nm or less, including structures, agglomerates or aggregates, which may 
have a size above the order of 100 nm but retain properties that are characteris-
tic to the nanoscale. Properties that are characteristic to the nanoscale include 
(i) those related to the large speciic surface area of the materials considered 
and/or (ii) speciic physicochemical properties that are different from those of 
the non-nanoform of the same material.
While the European Commission supported the European Parliament’s proposals 
for the deinition of “engineered nanomaterials,” as well as the labelling of nanoma-
terials in foodstuffs,79 it disagreed with the institution of a moratorium. In an opinion 
issued (2010),80 it stated that it:
does not agree with the EP assumption that the general methodology used for 
the risk assessment of foodstuffs would not be applicable for that of nanomateri-
als in food [. . .] and that, until speciic test methods are developed, no food with 
nanomaterials should be put on the EU market [. . .].
In line with the EFSA opinion of 10 February 2010, the Commission acknowl-
edges that additional safety tests and control tools need to be developed but that 
the methodology used for the risk assessment of foodstuffs remains valid [. . .].
The Commission is committed to only approve the marketing of food contain-
ing nanomaterials for which the food safety has been established.
79  See also Van Calster (2009).
80  Opinion of the Commission pursuant to Article 294, paragraph 7, point (c) of the Treaty on the 
Functioning of the European Union, on the European Parliament’s amendments to the Council’s posi-
tion regarding the proposal for a Regulation of the European Parliament and of the Council on novel 
foods, amending Regulation (EC) No. 1331/2008 and repealing Regulation (EC) No. 258/97 and 
Commission Regulation (EC) No. 1852/2001, COM (2010) 570 inal, 11.10.2010.
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81  Regulation (EU) No. 1169/2011 of the European Parliament and of the Council of 25 October 
2011 on the provision of food information to consumers, amending Regulations (EC) No. 1924/2006 
and (EC) No. 1925/2006 of the European Parliament and of the Council, and repealing Commission 
Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 
2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 
2008/5/EC and Commission Regulation (EC) No. 608/2004, OJ L 304/18, 22.11.2011.
82  Regulation (EC) No. 1333/2008 of the European Parliament and of the Council on food additives, 
OJ L 354/16, 31.12.2008.
83  Regulation (EC) No. 1935/2004 of the European Parliament and of the Council on materials and 
articles intended to come into contact with food, OJ L 338/4, 13.11.2004.
84  Regulation (EU) No. 10/2011 on plastic materials and articles intended to come into contact with 
food, OJ L 12/1, 15.1.2011.
85  It has been argued that nanomaterials performing a function other than that of authorized mono-
mers, other starting substances, macromolecules obtained from microbial fermentation, additives and 
polymer production aids may escape the authorization requirement; however, this point has not yet 
been adequately clariied by the European authorities.
In March 2011, following the prolonged failure of the European Parliament and 
the European Union Council to reach an agreement as to the review of the novel 
foods legislation (in particular with regard to cloning for food), the legislative review 
process collapsed. As a result, the 1997 Novel Foods Regulation remains still in force.
Despite the failed attempts at EU level to include speciic provisions for nano-
materials in the novel foods legislation, such provisions have been included in other 
pieces of food legislation. The recently introduced EU Food Labelling Regulation81 
establishes that all ingredients present in the form of engineered nanomaterials shall 
be clearly indicated in the list of ingredients, the names of such ingredients being 
followed by the word “nano” in brackets. The EU Regulation on food additives82 
establishes a uniform authorization system for food additives marketed in the EU, 
whether these are nano or not. However, it does specify that when a food additive 
is already approved under the Regulation, but there is, inter alia, a change in parti-
cle size, for example through nanotechnology, the food additive is to be considered 
as a different one—therefore, a new entry in the Community lists or a change in the 
speciications will need to be completed prior to its EU marketing. Finally, while 
the EU Framework Regulation on Food Contact Materials83 does not contain spe-
ciic nanomaterial provisions (despite that, in principle, it does cover nanomaterials), 
the recently introduced Regulation on Plastic Materials84 establishes concrete rules 
for plastic food contact materials and articles which contain nanomaterials. In par-
ticular, aside the generic requirements by which nanomaterials, too, need to abide, the 
Regulation provides that substances in nanoform (i) are only to be used if explicitly 
authorized and included in the, so-called, “Union list of authorised monomers, other 
starting substances, macromolecules obtained from microbial fermentation, additives 
and polymer production aids”85 and (ii) are not to beneit from the so-called “func-
tional barrier” exception, which allows for a derogation from the need for authoriza-
tion in certain cases of non-direct contact of the plastic with the food.
As a inal note, it should also be mentioned that, in the context of an ongoing 
review of the medical devices legislation, the European Commission is currently 
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86  For more information on the review process, see http://ec.europa.eu/health/medical-devices/ 
documents/revision/index_en.htm and D’Silva and Van Calster (2009).
87  Berkeley, Cal. Ordinance ch. 15.12, §15.12.040(I) (2006).
88  Berkeley, Cal. Ordinance ch. 15.12, §15.12.050(C)(7) (2006).
considering the introduction of a labeling requirement for nanomaterials, as well as 
the application of a more strict conformity assessment procedure for medical devices 
containing free nanomaterials.86 The adoption of the relevant proposals is planned 
for 2014, while implementation should, in principle, take place in the course of the 
period 2015–2019.
12.2.6.3 Local and state regulation in the US
12.2.6.3.1 Berkeley, CA
In December 2006, Berkeley, CA, indicated that it was tired of waiting for EPA to 
speciically regulate nanotechnology and amended its own hazardous material ordi-
nance to encompass engineered nanoscale materials. The City’s amended ordinance 
now states that “all facilities that manufacture or use manufactured nanoparticles 
shall submit a separate written disclosure of the current toxicology of the materi-
als reported, to the extent known, and how the facility will safely handle, monitor, 
contain, dispose, track inventories, prevent release and mitigate such material.”87 
Nanoscale materials covered by the ordinance include “all manufactured nanoparti-
cles deined as a particle with one axis<100 nm in length.”88
The City further issued disclosure guidelines in the Spring of 2007 for compa-
nies seeking more information on exactly how to comply with the amended ordinance 
(City of Berkeley, 2007). The guidelines indicated that the City was seeking ive types 
of toxicity data: inhalation, dermal, oral, genotoxic, and reproductive. Recognizing 
that this extensive toxicity data may not be available for most engineered nanoscale 
materials, the City’s guidelines stated that “if an exposure potential is present but 
insuficient toxicological information is available, a precautionary approach should be 
taken which assumes that the material is toxic.” Additionally, the guidelines mandate 
that companies reporting under the ordinance prioritize their activities involving engi-
neered nanoscale materials into four control bands depending upon the uncertainty of 
the toxicity and the possibility of exposure.
12.2.6.3.2 Cambridge, MA
In January 2007, Cambridge, MA, considered whether it needed its own nanomate-
rials ordinance patterned after Berkeley, CA. The City Manager asked Cambridge’s 
Director of Environmental Health to create a committee of experts to recommend 
a subsequent course of action (Cambridge Nanomaterials Advisory Committee, 
Cambridge Public Health Department, 2008). The Director put together a nanotech-
nology advisory committee which met for 6 months to consider various options. The 
committee was made up of public citizens, academic experts, private consultants, 
lawyers, industry representatives, and representatives from nongovernmental organi-
zations. Rather than jumping to conclusions, the committee heard detailed presenta-
tions on nanotoxicology issues, the oversight of nanomaterials in an academic setting, 
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89  Cal. Health & Safety Code, ch. 699, §57019 (2008), available at http://www.leginfo.ca.gov/cgi-bin/
waisgate?WAISdocID=21332418341+0+0+0&WAISaction=retrieve.
an overview of existing federal laws and regulations pertaining to nanoscale materi-
als, and an overview of existing nanoscale material risk management frameworks. In 
May 2008, the committee reported back to the City Manager with a written report pri-
marily focused on potential workplace exposure risks and those possibly posed to the 
general public through manufacturing processes (Cambridge Nanomaterials Advisory 
Committee, Cambridge Public Health Department, 2008). The report concluded that 
while the City should continue to monitor scientiic and legal developments, the exist-
ing science was too inconclusive to recommend creating any new city ordinance spe-
ciically aimed at engineered nanoscale materials.
12.2.6.3.3 State of California
In January 2009, California’s Department of Toxic Substances Control issued a formal 
chemical information call in a letter to 26 entities involved in the manufacturing of car-
bon nanotubes. The manufacturers have 1 year to respond to the letter under California 
Health and Safety Code Chapter 699.89 The data requested by the State include infor-
mation regarding the speciic products in which the carbon nanotubes are used; quan-
tities used; major customers; sampling detection and monitoring methods; quality 
assurance and quality control protocols; potential environmental risks; knowledge of 
the safety of carbon nanotubes in terms of occupational safety, public health, and the 
environment; worker protection methods; and environmental protection methods. The 
letter also poses three questions recipients should carefully consider before answer-
ing: “When released, does your material constitute a hazardous waste under California 
Health and Safety Code provisions? Are discarded off spec materials a hazardous 
waste? Once discarded are the carbon nanotubes you produce a hazardous waste?”
California has indicated that its data call in efforts for engineered nanoscale 
materials will not end with carbon nanotubes. Rather, it intends to issue a series of 
letters over the coming months, focusing on various types of engineered nanoscale 
materials of potential concern.
12.2.7 Product and tort liability in the US
As noted, in the EU, product and tort liability are organized exclusively along national 
lines, and a review within the context of this article is meaningless. Product and tort 
liability may be prevalent in all stages of the nanotechnology product legal life cycle, 
especially in the supply, manufacturing, and disposal stages. In the US, key tort liability 
theories are negligence, strict product liability, and intentional or reckless torts which 
may generate punitive damages. One of the biggest issues accompanying such potential 
tort liability is insurance coverage (Figure 12.6).
12.2.7.1 Negligence
If a manufacturer or supplier negligently makes a product which is then sold and 
injures a third party, that company may face lawsuits regarding the most basic form of 
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90  See, e.g., Briggs v. Washington Metropolitan Area Transit Authority, 481 F.3d 839 (2007); Japan 
Airlines co., Lt. v. Port Authority of New York and New Jersey, 178 F.3d 103 (2d Cir. 1999).
91  Alexander v. Pathinder, Inc., 189 F.3d 735 (8th Cir. 1999).
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tort liability—negligence. Simply put, a company may be found liable for the tort of 
negligence if the company failed to act reasonably in light of the circumstances pre-
sented in the case and that failure was a cause of a person’s actual injury.90 The factual 
focus under this theory is whether the manufacturer acted reasonably in the particular 
situation at hand and owed the injured party that duty.91 The tort theory of negligence 
became most prominent in the 1940s and 1950s. Injured plaintiffs had to prove that a 
manufacturer acted outside the standard of normal care. This was sometimes dificult 
to prove, and courts ultimately started pushing strict liability toward manufacturers for 
public policy reasons. In the 1960s, California led the way toward modern strict liabil-
ity for product defects without regard to fault or negligence by the manufacturer.
12.2.7.2 Product liability
Rather than focusing on a manufacturer’s conduct, the legal theory of strict product 
liability focuses on the product itself. If the product is defective in any demonstra-
ble way, liability attaches and the manufacturer may be held liable for the injuries 
of anyone hurt by the product. This type of tort liability is most prevalent in the 
manufacturing stage of our nanotechnology product legal life cycle.
According to Black’s Law Dictionary (1979, p. 1275), strict liability means lia-
bility “without fault, when neither care nor negligence, neither good faith nor bad 
faith, neither knowledge nor ignorance will save the defendant.” Product liability is 
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strict liability. A manufacturer can be liable for injuries related to its product even 
if it did not act negligently, in bad faith, or in ignorance. Damages may include 
compensation for economic pain and suffering, as well as punitive damages in cer-
tain circumstances. There are three primary types of product liability claims: design 
defect, manufacturing defect, and failure to adequately warn or instruct users.
12.2.7.2.1 Design defects
“Design defect” claims are those that are brought against a manufacturer or supplier 
when reasonably foreseeable risks of injury from the product could have been reduced 
or avoided through the implementation of a reasonable alternative design. A design 
defect occurs when there is something fundamental to a product’s design that causes 
unreasonable risk of injury. Under the Restatement of Torts, a product is defectively 
designed when it is sold if “the foreseeable risks of harm posed by the product could 
have been reduced or avoided by the adoption of a reasonable alternative design, and 
the omission of the alternative design renders the product not reasonably safe.”92 When 
determining whether a design was defective in any given case, courts often balance the 
likelihood and gravity of potential injury against the utility of the product, the avail-
ability of other safer products to meet the same need, the obviousness of the use and 
potential injury, and the ability to eliminate or minimize the danger without seriously 
impairing the product or making it unduly expensive.93 Thus, determining whether a 
product has a design defect is often a complicated task. Design defect claims are the 
most likely type to be asserted against manufacturers using engineered nanoscale 
materials in their products. A consumer who is exposed to nanoscale materials from 
a product he or she purchases and is subsequently injured will most likely claim that 
the very design of the product was defective. The consumer’s attorney will allege that 
existing scientiic studies at the time of manufacture highlighted the potential exposure 
risks to the particular nanoscale material in question and that the use of this material 
in the product was unreasonable given these risks. The scientiic literature has not yet 
reached the point to make these types of claims attractive to plaintiffs’ attorneys. Thus 
far, there have been no design defect product liability claims iled against a manufac-
turer of engineered nanoscale materials.
12.2.7.2.2 Manufacturing defect
“Manufacturing defect” claims are those that are asserted against a manufacturer 
or supplier when a product is safely designed, but the product in question departed 
from its intended design and injured someone.94 A manufacturing defect occurs 
92  Restatement (Third) of Torts §2 (1998).
93  Restatement (Third) of Torts §2 cmt. d, II(B) (1998) (quoting Radiation Technology, Inc. v. Ware 
Constr. Co., 445 So.2d 329 (Fla. 1983)) (emphasis added). For other examples of courts applying 
this basic reasoning see also, Brooks c. Beech Aircraft Corp., 902 P.2d 54 (N.M. 1995); Claytor v. 
General Motors Corp., 286 S.E.2d 129 (S.C. 1982) (describing South Carolina’s risk balancing test).
94  Restatement (Third) of Torts §2(a) (1998). See also Caterpillar Tractor Co. V. Beck, 593 P.2d 871, 
881 (Alaska 1979); Barker v. Lull Engineering Co., 573 P.2d 443, 454 (Cal. 1978) (deining a manu-
facturing defect as one that “differs from manufacturer’s intended result or other ostensible identical 
units of the same product line”).
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96  Hoven v. Kelble, 256 N.W.2d 379, 391 (Wis. 1977).
97  Restatement (Third) of Torts §2(c) (1998).
98  Restatement (Third) of Torts §2(c) cmt. i (1998).
99  Restatement (Third) of Torts §2(c) cmt. i (1998).
95  Restatement (Third) of Torts §2 cmt. a. (1998).
when a “product departs from its intended design even though all possible care was 
exercised in the preparation or marketing of the product.”95 An example would be 
if the design of a product is completely safe and called for the use of one speciic 
engineered nanoscale material, but the manufacturer substituted a cheaper alterna-
tive and the substitution somehow ended up hurting a consumer. If the use of the 
substituted material causes a consumer injury and the consumer’s lawyer learns of 
the deviation, he may allege that because the design was not followed to the let-
ter the product was defectively manufactured and the manufacturer is strictly liable 
for his client’s injuries. Again, a manufacturing defect product liability claim is a 
strict liability tort. Liability may be imposed regardless of the amount of effort a 
manufacturer puts into the manufacturing and quality control processes. The theory 
is that strict liability makes a good deterrent and increases safety.96 Thus far, there 
have been no manufacturing defect claims against a manufacturer of an engineered 
nanoscale product based on the “nano-ness” of that product.
12.2.7.2.3 Failure to adequately warn or instruct
Product liability claims for failure to adequately warn or instruct a consumer about 
the dangers presented by a product arise when the foreseeable risk of injury could 
have been avoided through use of reasonable instructions or warnings provided by the 
manufacturer. As a legal matter, inadequate instructions or warnings result “when the 
foreseeable risks of harm posed by the product could have been reduced or avoided 
by the provision of reasonable instructions where warnings and the omission of the 
instructions or warnings render the product not reasonably safe.”97 Generally, warn-
ings and instructions accompanying a product must “alert users and consumers to the 
existence and nature of product risks so that they can prevent harm either by appro-
priate conduct during use or consumption or by choosing not to use or consume.”98 
Additionally, manufacturers are required to warn users about nonobvious and not 
generally known risks that are inherent in using the product. The issue of how much 
warning is suficient is generally driven by the facts and circumstances in a particu-
lar case. Generally under the Restatement of Torts, “warnings must be provided for 
inherent risks that reasonably foreseeable product users and consumers would rea-
sonably deem material were signiicant in deciding whether to use or consume the 
product.”99 On the other hand, warnings are not generally required for open and obvi-
ous risks. Currently, the science is still out regarding whether engineered nanoscale 
materials may present EHS risks in realistic exposure settings. Manufacturers, how-
ever, should be aware of this developing body of scientiic literature, determine 
whether their products are suficiently safe in light of these studies, and carefully con-
sider what nanospeciic safety warnings and instructions (if any) should accompany 
products under these standards.
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12.2.7.2.4 Punitive damages
Punitive damages are awarded in civil tort actions in excess of actual compensatory 
damages due to a defendant’s conduct which the judicial system inds particularly 
egregious or malicious. There is no independent cause of action for punitive dam-
ages, and simply committing a “standard” tort will not warrant punitive damages by 
itself. The conduct in question must be reckless, egregious, “ruthless,” outrageous, 
“evil,” and/or with malice.100 Punitive damages are awarded to punish and make an 
example out of the defendant to deter similar future behavior.101
Although it is sometimes hard to determine from awards in modern tort cases, 
punitive damages are (or used to be) generally disfavored by the law and only 
awarded in very limited circumstances. Because of complaints about monetary 
“windfalls” to successful plaintiffs and their attorneys, some states have capped 
punitive damage awards and the US Supreme Court has determined that punitive 
damages must bear some reasonable relationship and size to the underlying con-
duct which generated the tort claim.102 For purposes of our nanotechnology product 
legal life cycle, punitive damages for intentional torts may occur at any juncture a 
tort may occur. “Intentionally” setting out to hurt someone is never part of a busi-
ness plan, however, nanotechnology businesses must be aware that if they conceal 
potential EHS risks posed by their products—or turn a blind eye toward them—
they may be open to intentional tort claims supporting punitive damages.
12.2.7.3 Commercial insurance coverage
One of the largest issues accompanying potential product and tort liability claims is 
whether commercial insurance will cover any such occurrences. Without insurance, 
it is almost impossible to successfully operate in the modern commercial world. 
From the insurers’ perspective, it is dificult to determine exactly how to insure a 
potential new risk with unknown health effects and exposure rates.
One insurer theorizes that nanotechnology insurance coverage issues will 
appear in three stages (Blaunstein, 2006). First will be the Early Study Period dur-
ing which nanotechnology risks may already be covered by existing commercial 
insurance policies, but are not separately delineated. It is during this stage that the 
insurance industry will strive to assess potential risks and exposures. The second 
stage is the Apprehensive Phase during which the insurance industry may attempt 
to reduce coverage exposure by using sublimits and claims made coverage. The 
third and inal phase is the Mature Phase during which insurance companies offer 
specialized and customized insurance, solutions for their nanotechnology insureds. 
As of 2006, this insurer believed that we are in the Early Study Period.
In 2008, Lloyd’s of London identiied several options for insurers seeking to deal 
with the potential risks posed by issuing commercial insurance coverage for prod-
ucts and operations involving engineered nanoscale materials (Baxter, 2008). Lloyd’s 
102  See, e.g., Paciico Mut. Life Ins. Co. v. Haslip, 499 US 1 (1991).
100  See, e.g., Choctaw Maid Farms, Inc. v. Hailey, 822 So.2d 911 (Miss. 2002); Wearer v. Stafford, 8 P.3d 
1234 (Id. 2000); Doe v. Isaacs, 579 S.E.2d 174 (Va. 2003); Horner v. Byrnett, 511 S.E.2d 342 (N.C. 1999).
101  See, e.g., PPG Industries, Inc. v. Transamerica Inc. Co., 975 P.2d 652 (Ca. 1999).
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103  Borrowed from Cousy (2006), 11 citing Nicolas De Saedeleer exposition of the development of 
the law on environmental impairment in Les principes du pollueur, de prévention et de précaution. 
Essai sur le genèse et la protée juridique de quelques princiles du droit de l’environnement (1990).
noted that insurers could choose to completely exclude coverage for nanotechnology, 
exclude nanotechnology from full coverage and then provide separate limited cover-
age for those risks, and/or only accept claims within a ixed period of time after a pol-
icy is written which would limit latent exposure. In the interim, Lloyd’s noted that it 
will continue to monitor and research emerging risks potentially related to engineered 
nanoscale materials. Most other major commercial insurers are taking this same “wait 
and see” approach (Germano, 2008).
In the fall of 2008, however, one US insurance company—Continental Western 
Insurance Group—issued the irst nanospeciic commercial insurance exclusion in the 
US. The company explained that “the intent of this exclusion is to remove coverage 
for the, as of yet, unknown and unknowable risks created by-products and processes 
that involve nanotubes. The exclusion is being added to make you and your customers 
explicitly aware of our intent not to cover injury and/or damage arising from nano-
tubes, as used in products and processes” (Monica, 2008). Continental compared the 
possible risks insurers face by covering applications involving carbon nanotubes to 
those created by insuring asbestos in its early days. The speciic exclusion issued by 
Continental covers “bodily injury, property damage, and personal and advertising 
injury related to the exposure of nanotubes and nanotechnology in any form. This 
includes the use of, contact with, existence of, presence of, proliferation of, discharge 
of, dispersal of, seepage of, migration of, release of, escape of, or exposure to nano-
tubes or nanotechnology” (Monica, 2008).
It remains to be seen whether Continental actually implemented its nanospeciic 
exclusion. Shortly after posting these documents on its website, BNA published an 
article about the exclusion which created a stir. The documents were then quickly 
removed from Continental’s website.
12.2.8 Product and tort liability in the EU
In the EU, product and tort liability are only regulated at the EU level in piecemeal 
fashion. Noncontractual liability is an extensive regulatory instrument that has pro-
gressively been applied to new technologies. It allows courts signiicant leeway for 
interpretation (depending on jurisdiction) to apply its instruments to diverse situations 
of safety, health, and environmental damage (as an infringement of property rights).
It is common knowledge, however, that noncontractual liability is regulation 
applied ex post the harming event, and most times when tackling new developments, 
also ex post speciic legislation. Noncontractual liability is thus a “curative model” 
par excellence, where the infringement of a right is compensated for in iscal terms.103 
The ongoing development of such notions as “material increase of risk,” “foresee-
ability of risk,” “sphere of risk,” “high level of probability,” or “loss of chance,” tak-
ing known risks into account, inclines one to think that noncontractual liability as a 
regulatory instrument may yet adopt a preventive stance. A certainty, however, is 
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that this instrument does not employ an “anticipatory approach”104—a precaution to 
uncertainty.
Even in its preventive role, with nano and new technologies noncontractual liabil-
ity will stall. The role relates to known risks, and not complete known unknowns, and 
unknown unknowns. General causality is still a big barrier. “[U]nless and until a sig-
nature illness or condition is discovered,”105 noncontractual liability will not temper 
the proliferation and use of nanotechnologies. A deeper, more productive investiga-
tion, and establishment of the effects of nanomaterials, the epidemiology, and the whys 
and the hows need to be mandated and undertaken for noncontractual liability to have 
any success as a regulatory force. An interim way around this problem would be the 
instatement of risk as a head of damage, much promulgated in this text. Even with-
out the frills of a new liability instrument, risk as a head of damage would enable the 
liability regulatory tool to at least cater for those known unknowns.
In the event of diffuse pollution from nanomaterials, and in the case of transient 
minimal exposure, the effects issue is also relevant, but so is detection. Unless a spe-
ciic pollution/harm is found to be unequivocally and uniquely attributable to a cer-
tain type of nanomaterial, hence identifying said pollution/harm automatically implies 
said speciic nanomaterial, detection mechanisms will still be an issue. Perhaps what is 
required is some sort of extended producer responsibility, to do away with noncontrac-
tual liability’s deicits—a “tax on uncertainty,” which needless to say, will be shifted 
onto the consumers.106
It would seem that in the EU and in its Member States, as yet there are still too 
many lacunae for noncontractual liability to effectively operate as a regulatory instru-
ment. “Civil liability is static, in the sense that judgement is given on a situation that 
has occurred in the past, taking into account the state of science and technology that 
existed at the time.”107 Let us face it, noncontractual liability was not created to apply 
ex ante reasoning of a damaging event, and though it has developed tools with which 
to challenge technological advances, they are not yet sophisticated enough to tackle 
largely known unknowns and more so unknown unknowns. This is not to say that this 
104  Borrowed from Cousy (2006), 11 citing Nicolas De Saedeleer exposition of the development of 
the law on environmental impairment in Les principes du pollueur, de prévention et de précaution. 
Essai sur le genèse et la protée juridique de quelques princiles du droit de l’environnement (1990).
105  Wernette (2009).
106  This recommendation is not unlike the French FIVA (Fonds d’Indemnisation des Victimes de 
l’Amiante) set up in 1999/2000 for victims of asbestos exposure, for reasons of problems regarding 
conditions of causation, prescription, and insolvency of liable companies, though it has to be said 
that this was state funded, with the state reserving a right of subrogatory action against the liable 
companies. The scheme offered réparation intégrale based upon the presumption that the illness was 
caused by asbestos. Those who accepted compensation from the fund could resort to no other right 
of recourse. Were they provided with an unsatisfactory offer, this could be appealed and the victims 
could bring a liability claim for faute inexcusable of the employer. In Germany no asbestos cases 
were brought before the courts for liability for personal injury, as compensation was catered for by a 
state social insurance scheme. Information obtained from Martin-Casals (2010).
107  Van Dam (2006).
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regulatory instrument should not be wielded when these unknowns become better 
known and understood.108
12.3 Conclusion
The regulatory debate on nanotechnologies is evidently heating up. Given the—largely 
owed to increased scrutiny and pressure exercised by the European Parliament—trend 
of nanospeciic regulation in the EU (including the introduction of a deinition for nano-
materials, the use of “positive”—i.e., authorization—lists for nanomaterials in a num-
ber of core legislative instruments, and the publication of detailed guidance documents 
on nanomaterials) industry is now faced with a much more urgent risk assessment and 
management exercise than previously envisaged. Under the new US administration, too, 
various agencies have been tasked to review the regulatory oversight of nanotechnolo-
gies more urgently. In such a regulatory environment, monitoring manufacturer compli-
ance and potential liability over the full product life cycle becomes even more important. 
The legal framework set forth above provides a good starting point for this analysis 
when overlaid by the various regulatory and/or liability pressure points. As Figure 12.7 
108  See further in Van Claster and Borg.
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depicts, taken all at once a complex legal web develops which can appear daunting. 
However, breaking down the issues piece by piece as outlined above should prove useful 
to attorneys, businesses, regulators, and nongovernmental organizations examining these 
issues. By recognizing how the various stages of a nanoproduct’s life cycle interact with 
legal and regulatory issues, a lexible nanotechnology legal framework results, which 
should be valuable to those examining nano-related EHS legal issues.
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